0001683168-18-002736.txt : 20180914 0001683168-18-002736.hdr.sgml : 20180914 20180914074247 ACCESSION NUMBER: 0001683168-18-002736 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 38 CONFORMED PERIOD OF REPORT: 20161231 FILED AS OF DATE: 20180914 DATE AS OF CHANGE: 20180914 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CANNAPHARMARX, INC. CENTRAL INDEX KEY: 0001081938 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 274635140 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-27055 FILM NUMBER: 181070065 BUSINESS ADDRESS: STREET 1: 2 PARK PLAZA, STE. 1200-B CITY: IRVINE STATE: CA ZIP: 92614 BUSINESS PHONE: 949-652-6838 MAIL ADDRESS: STREET 1: 2 PARK PLAZA, STE. 1200-B CITY: IRVINE STATE: CA ZIP: 92614 FORMER COMPANY: FORMER CONFORMED NAME: GOLDEN DRAGON HOLDING CO. DATE OF NAME CHANGE: 20110125 FORMER COMPANY: FORMER CONFORMED NAME: CCVG, INC. DATE OF NAME CHANGE: 20101117 FORMER COMPANY: FORMER CONFORMED NAME: CONCORD VENTURES, INC. DATE OF NAME CHANGE: 20071003 10-K 1 cannapharmarx_10k-123116.htm FORM 10-K

U.S. SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

__________________

FORM 10-K

__________________

(Mark one)

x	ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2016

o	TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from ________________ to________________________.

Commission File Number: 000-27055

CANNAPHARMARX, INC.

(Exact name of registrant as specified in its charter)

Delaware		27-4635140
(State or other jurisdiction of incorporation or organization)		(IRS Employer Identification No.)

2 Park Plaza Suite 1200B Irvine, CA	92614	(949) 652-6838
(Address of principal executive office)	(Zip Code)	(Registrant’s telephone number, Including area code)

Securities registered pursuant to Section 12(b) of the Act: None.

Securities registered pursuant to Section 12(g) of the Act: Common Stock.

Title of each class		Name of each exchange on which registered
Common Stock, $0.0001 par value		OTC Pink Sheets

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. o Yes x No

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. o Yes x No

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. o Yes x No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). o Yes x No

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§229.405 of this chapter) is not contained herein, and will not be contained, to the best of the registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. o Yes x No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one)

Large accelerated filer o	Accelerated filer o
Non-accelerated filer o	Smaller Reporting Company x
Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). x Yes o No

State the aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant’s most recently completed second fiscal quarter on June 30, 2016 was $8,397,371.

As of September 14, 2018, the Registrant had 17,960,741 shares of Common Stock issued and outstanding.

DOCUMENTS INCORPORATED BY REFERENCE

None

TABLE OF CONTENTS

		Page No.
PART I
Item 1.	Business	3
Item 1A.	Risk Factors	4
Item 1B.	Unresolved Staff Comments	4
Item 2	Properties	4
Item 3.	Legal Proceedings	5
Item 4.	Mine Safety Disclosures	5

PART II
Item 5.	Market for the Registrant’s Common Equity and Related Stockholder Matters and Issuer Purchases of Equity Securities	6
Item 6.	Selected Financial Data	8
Item 7.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	8
Item 7A.	Quantitative and Qualitative Disclosures About Market Risk	13
Item 8.	Financial Statements and Supplementary Data	13
Item 9.	Changes in and Disagreements on Accounting and Financial Disclosure	13
Item 9A.	Controls and Procedures	14
Item 9B.	Other Information	15

PART III
Item 10.	Directors, Executive Officers and Corporate Governance	16
Item 11.	Executive Compensation	18
Item 12.	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	20
Item 13.	Certain Relationships and Related Transactions, and Director Independence	20
Item 14.	Principal Accounting Fees and Services	21

PART IV
Item 15.	Exhibits, Financial Statement Schedules	22

	Signatures	23

FORWARD LOOKING STATEMENTS

This Annual Report on Form 10-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The statements regarding Capital Art, Inc. contained in this Report that are not historical in nature, particularly those that utilize terminology such as “may,” “will,” “should,” “likely,” “expects,” “anticipates,” “estimates,” “believes” or “plans,” or comparable terminology, are forward-looking statements based on current expectations and assumptions, and entail various risks and uncertainties that could cause actual results to differ materially from those expressed in such forward-looking statements.

Important factors known to us that could cause such material differences are identified in this Report. We undertake no obligation to correct or update any forward-looking statements, whether as a result of new information, future events or otherwise. You are advised, however, to consult any future disclosures we make on related subjects in future reports to the SEC.

PART I

Item 1. Business.

History

We were originally incorporated in the State of Colorado in August 1998 under the name “Network Acquisitions, Inc.” We changed our name to Cavion Technologies, Inc. in February 1999 and subsequently to Concord Ventures, Inc. in October 2006.

On December 21, 2000, we filed for protection under Chapter 11 of the United States Bankruptcy Code. In connection with the filing, on February 16, 2001, we sold our entire business, and all of our assets, for the benefit of our creditors. After the sale, we still had liabilities of $8.4 million and were subsequently dismissed by the Court from the Chapter 11 reorganization, effective March 13, 2001, at which time the last of our remaining directors resigned. On March 13, 2001, we had no business or other source of income, no assets, no employees or directors, outstanding liabilities of approximately $8.4 million and had terminated our duty to file reports under securities law. In February 2008, we were re-listed on the OTC Bulletin Board.

In April 2010, we re-domiciled in Delaware under the name CCVG, Inc. (“CCVG”). Effective December 31, 2010, CCVG completed an Agreement and Plan of Merger and Reorganization y (the “Reorganization") which provided for the merger of two of our wholly owned subsidiaries. As a result of this reorganization our name was changes to “Golden Dragon Inc.”, which became the surviving publicly quoted parent holding company.

On May 9, 2014, we entered into a Share Purchase Agreement (the “Share Purchase Agreement”) with CannaPharmaRX, Inc., a Colorado corporation (“Canna Colorado”), and David Cutler, a former President, Chief Executive Officer, Chief Financial Officer and director of our Company. Under the Share Purchase Agreement, Canna Colorado purchased 1,421,120 shares of our common stock from Mr. Cutler and an additional 9,000,000 restricted common shares directly from us.

On May 15, 2014, as amended and effective January 29, 2015, we entered into an Agreement and Plan of Merger (the “Merger”) pursuant to which Canna Colorado became a subsidiary of our Company. In October 2014, we changed our legal name to “CannaPharmaRx, Inc.”

Pursuant to the Merger, all of the shares of our common stock previously owned by Canna Colorado were cancelled. As a result of the aforesaid transactions we became an early-stage pharmaceutical company whose purpose was to advance cannabinoid research and discovery using proprietary formulation and drug delivery technology then under development.

In April 2016, we ceased operations. Our then management resigned their respective positions with our Company, with the exception of Mr. Gary Herick, who remains as one of our officers and directors.

As a result, we are now considered a “shell” company as defined under the Securities Exchange Act of 1934, as amended.

Our executive offices are located at Our principal place of business is located at 2 Park Plaza, Suite 1200B, Irvine, CA, 92614, phone (949) 652-6838. Our website address is www.cannapharmarx.com.

Employees

During 2016 and as of the date of this report we have no employees except our current management. See “Part III, Item 10, Management” below.

Competition

We are competing with other publicly held companies who are also seeking to acquire or otherwise consolidate with an existing business. We believe that the only thing that may separate us from these competitors is our interest in the cannabis industry, but there are no assurances that this provides any competitive edge. Most of our competitors have greater resources, both financial and otherwise, than the resources presently available to us.

Intellectual Property

We currently do not hold any patents or patent applications. We hold one registered trademark, RECRUIT Registry^™. This report contains additional trademarks, service marks, or trade names of others. Our use or display of other parties’ trademarks, service marks or trade names is not intended to imply and does not imply a relationship with, or endorsement of, such parties. We seek to protect our proprietary information, including our trade secrets and proprietary know-how, by requiring our employees, consultants and other advisors to execute confidentiality agreements upon the commencement of their employment or engagement. These agreements generally provide that all confidential information developed or made known during the course of the relationship with us be kept confidential and not be disclosed to third parties except in specific circumstances. In the case of our employees, the agreements also typically provide that all inventions resulting from work performed for us, utilizing our property or relating to our business and conceived or completed during employment shall be our exclusive property to the extent permitted by law. Where appropriate, agreements we obtain with our consultants also typically contain similar assignment of invention provisions. Further, we generally require confidentiality agreements from business partners and other third parties that receive our confidential information.

Item 1A. Risk Factors.

We are a smaller reporting company and not required to include this disclosure in our Form 10-K annual report.

ITEM 1B. UNRESOLVED STAFF COMMENTS

None.

Item 2. Properties.

During our fiscal year ended December 31, 2016, Mr. Herick provided office space at his home at no cost to the Company.

On April 1, 2018 we changed our principal place of business to 2 Park Plaza, Suite 1200 – B. Irvine, CA. 92614, phone: 949-652-6838. This space is provided to us on a twelve month term by a company to which Mr. Nicosia, one of our directors, serves as Chief Executive Officer. Our monthly rent is $1,000, however, as of the date of this filing, we have not made any rent payments and continue to accrue those amounts as accounts payable. We believe this location will be sufficient for our current business purposes until such time an acquisition is consummated.

Item 3. Legal Proceedings.

On October 30, 2014, Gary M. Cohen (“Mr. Cohen”), former president, Chief Operating Officer and board member of CannaRx, filed a lawsuit against CannaRx in the Circuit Civil Court of the Thirteenth Judicial District in and for Hillsborough County, Florida, in Division T. On November 11, 2014, we sued Mr. Cohen in the U.S. District Court for the District of New Jersey, alleging tortious interference with business relationships and defamation due to publishing fake press releases on the Internet concerning his lawsuit against us.

On March 25, 2015, we reached an agreement with Mr. Cohen in principle to the terms of a settlement agreement that resolved the aforementioned lawsuits. As part of that agreement in principle we agreed to purchase all of Mr. Cohen’s 2,250,000 shares for a purchase price of $350,000, with $85,000 payable up front and the remainder payable in equal installments of $15,000 per month over the next 17 months, and a final payment of $10,000 in the eighteenth month. In addition to this $350,000 cash expense, we issued Mr. Cohen 600,000 restricted shares of our common stock.

FINRA Action

On January 29, 2015, we received a deficiency notice from the Financial Industry Regulatory Authority (“FINRA”), stating that FINRA would not process our name change from October 2014 due to questions about our ownership raised in the Cohen litigation described above. We appealed the notice, arguing among other things that the ownership of our Company was not at issue in the Cohen litigation. On March 20, 2015, FINRA reversed the deficiency notice and subsequently processed ours request to change our name and trading symbol.

In addition to the above-mentioned matters, we may be subject, from time to time, to various legal proceedings and claims. Any such claims, whether with or without merit, could be time-consuming and expensive to defend and could divert management’s attention and resources. We cannot assure that the outcome of all current or future litigation will not have a material adverse effect on us and our results of operation.

ITEM 4. MINE SAFETY DISCLOSURES

Not Applicable.

PART II

Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.

Market Information

Our common stock is quoted on the over the counter pink sheets under the trading symbol “CPMD.” Trading volume in our Common Stock is very limited. As a result, the trading price of our Common Stock is subject to significant fluctuations.

There can be no assurance that a liquid market will develop in the foreseeable future.

Transfer of our common stock may also be restricted under the securities or blue sky laws of certain states and foreign jurisdictions. Consequently, investors may not be able to liquidate their investments and should be prepared to hold the common stock for an indefinite period of time.

The following table sets forth the high and low bid quotations for our Common Stock as reported on the on the pink sheets for the periods indicated.

	High		Low
Fiscal 2015	$		$

First Quarter		2.50		3.45
Second Quarter		3.60		3.00
Third Quarter		3.50		1.60
Fourth Quarter		3.00		1.10

Fiscal 2016

First Quarter		2.00		0.40
Second Quarter		0.55		0.40
Third Quarter		0.90		0.20
Fourth Quarter		0.70		0.35

As of September 11, 2018, the closing price of our Common Stock was. $0.50 per share.

The Securities Enforcement and Penny Stock Reform Act of 1990

The Securities and Exchange Commission has also adopted rules that regulate broker-dealer practices in connection with transactions in penny stocks. Penny stocks are generally equity securities with a price of less than $5.00 (other than securities registered on certain national securities exchanges or quoted on the NASDAQ system, provided that current price and volume information with respect to transactions in such securities is provided by the exchange or system).

As of the date of this Report, our Common Stock is defined as a “penny stock” under the Securities and Exchange Act. It is anticipated that our Common Stock will remain a penny stock for the foreseeable future. The classification of penny stock makes it more difficult for a broker-dealer to sell the stock into a secondary market, which makes it more difficult for a purchaser to liquidate his/her investment. Any broker-dealer engaged by the purchaser for the purpose of selling his or her shares in us will be subject to Rules 15g-1 through 15g-10 of the Securities and Exchange Act. Rather than creating a need to comply with those rules, some broker-dealers will refuse to attempt to sell penny stock.

The penny stock rules require a broker-dealer, prior to a transaction in a penny stock not otherwise exempt from those rules, to deliver a standardized risk disclosure document prepared by the Commission, which:

contains a description of the nature and level of risk in the market for penny stocks in both public offerings and secondary trading;

contains a description of the broker's or dealer's duties to the customer and of the rights and remedies available to the customer with respect to a violation to such duties or other requirements of the Securities Act of 1934, as amended;

contains a brief, clear, narrative description of a dealer market, including "bid" and "ask" prices for penny stocks and the significance of the spread between the bid and ask price;

contains a toll-free telephone number for inquiries on disciplinary actions;

defines significant terms in the disclosure document or in the conduct of trading penny stocks; and

contains such other information and is in such form (including language, type, size and format) as the Securities and Exchange Commission shall require by rule or regulation.

The broker-dealer also must provide, prior to effecting any transaction in a penny stock, to the customer:

the bid and offer quotations for the penny stock;

the compensation of the broker-dealer and its salesperson in the transaction;

the number of shares to which such bid and ask prices apply, or other comparable information relating to the depth and liquidity of the market for such stock; and

monthly account statements showing the market value of each penny stock held in the customer's account.

In addition, the penny stock rules require that prior to a transaction in a penny stock not otherwise exempt from those rules; the broker-dealer must make a special written determination that the penny stock is a suitable investment for the purchaser and receive the purchaser's written acknowledgment of the receipt of a risk disclosure statement, a written agreement to transactions involving penny stocks, and a signed and dated copy of a written suitability statement. These disclosure requirements will have the effect of reducing the trading activity in the secondary market for our stock because it will be subject to these penny stock rules. Therefore, stockholders may have difficulty selling their securities.

Holders

As of December 31, 2016, there were 17,960,741 shares of our common stock issued and outstanding, which were held by 205 stockholders of record, not including those persons holding shares in “street name.” As of the date of this Report there were 17,960,741 Common Shares issued and outstanding, held by 205 holders of record, not including those persons holding shares in “street name.”

Stock Transfer Agent

Our stock transfer agent for our securities is Mountain Share Transfer, Inc., 2030 Powers Ferry Road SE, Suite 212, Atlanta, GA 30339. Their telephone number is (303) 460-1149.

Dividends

We have never declared or paid any cash dividends on our common stock. We currently intend to retain future earnings, if any, to finance the expansion of our business. As a result, we do not anticipate paying any cash dividends in the foreseeable future.

Reports

We are subject to certain reporting requirements and furnish annual financial reports to our stockholders, certified by our independent accountants, and furnish unaudited quarterly financial reports in our quarterly reports filed electronically with the SEC. All reports and information filed by us can be found at the SEC website, www.sec.gov. As of the date of this report we need to file quarterly and annual reports for 2016, 2017 and 2018 which we intend to file in the near future.

Item 6. Selected Financial Data.

As a smaller reporting company, we are not required to provide this information.

Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations.

The following discussion should be read in conjunction with our audited financial statements and notes thereto included herein. In connection with, and because we desire to take advantage of, the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, we caution readers regarding certain forward looking statements in the following discussion and elsewhere in this Report and in any other statement made by, or on our behalf, whether or not in future filings with the Securities and Exchange Commission. Forward looking statements are statements not based on historical information and which relate to future operations, strategies, financial results or other developments. Forward looking statements are necessarily based upon estimates and assumptions that are inherently subject to significant business, economic and competitive uncertainties and contingencies, many of which are beyond our control and many of which, with respect to future business decisions, are subject to change. These uncertainties and contingencies can affect actual results and could cause actual results to differ materially from those expressed in any forward looking statements made by, or on our behalf. We disclaim any obligation to update forward looking statements.

Overview and History

In April 2010, we re-domiciled in Delaware under the name CCVG, Inc. (“CCVG”). Effective December 31, 2010, CCVG completed an Agreement and Plan of Merger and Reorganization (the “Reorganization") which provided for the merger of two of our wholly owned subsidiaries. As a result of this reorganization our name was changes to “Golden Dragon Inc.”, which became the surviving publicly quoted parent holding company.

In April 2016, we ceased operations. Our then management resigned their respective positions with our Company, with the exception of Mr. Gary Herick, who remains as one of our officers and directors.

As a result, we are now considered a “shell” company as defined under the Securities Exchange Act of 1934, as amended.

Our executive offices are located at Our principal place of business is located at 2 Park Plaza, Suite 1200B, Irvine, CA, 92614, phone (949) 652-6838. Our website address is www.cannapharmarx.com.

Because we have not generated any revenues during our prior two years, following is our Plan of Operation.

PLAN OF OPERATION

As of the date of this Report we intend to engage in what we believe to be synergistic acquisitions or joint ventures with a company or companies that we believe will enhance our business plan. Ultimately, our intent is to become a national or internationally branded cannabis cultivation company, or otherwise engage in the cannabis industry. However, if an opportunity in another industry arises we will review that opportunity as well. One of the benefits to our being a reporting and publicly traded company, is to allow us to utilize our securities as consideration for some, or all of the purchase price of these potential acquisitions. There are no assurances we will be able to consummate any acquisitions using our securities as consideration, or at all.

There are numerous things that will need to occur in order to allow us to implement this aspect of our business plan and there are no assurances that any of these developments will occur, or if they do occur, that we will be successful in fully implementing our plan.

Management will seek out and evaluate businesses for acquisition. The integrity and reputation of any potential acquisition candidate will first be thoroughly reviewed to ensure it meets with management’s standards. Once targeted as a potential acquisition candidate, we will enter into negotiations with the potential candidate and commence due diligence evaluation, including its financial statements, cash flow, debt, location and other material aspects of the candidate’s business. If we are successful in our attempts to acquire a company or companies utilizing our securities as part or all of the consideration to be paid, our current shareholders will incur dilution.

In implementing a structure for a particular acquisition, we may become a party to a merger, consolidation, reorganization, joint venture, asset purchase, or licensing agreement with another corporation or entity. We may also acquire stock or assets of an existing business. Upon the consummation of a transaction, it is likely that our present management and shareholders will no longer be in control of our Company.

As part of our investigation, our officers and directors will meet personally with management and key personnel, may visit and inspect material facilities, obtain independent analysis of verification of certain information provided, check references of management and key personnel, and take other reasonable investigative measures, to the extent of our limited financial resources and management expertise. The manner in which we participate in an acquisition will depend on the nature of the opportunity, the respective needs and desires of us and other parties, the management of the acquisition candidate and our relative negotiation strength.

We will participate in an acquisition only after the negotiation and execution of appropriate written agreements. Although the terms of such agreements cannot be predicted, generally such agreements will require some specific representations and warranties by all of the parties thereto, will specify certain events of default, will detail the terms of closing and the conditions which must be satisfied by each of the parties prior to and after such closing, will outline the manner of bearing costs, including costs associated with our attorneys and accountants, will set forth remedies on default and will include miscellaneous other terms.

Depending upon the nature of the acquisition, including the financial condition of the acquisition company, as a reporting company under the Securities Exchange Act of 1934 (“34 Act “), it will be necessary for such acquisition candidate to provide independent audited financial statements. We will not acquire any entity which cannot provide independent audited financial statements within a reasonable period of time after closing of the proposed transaction. If such audited financial statements are not available at closing, or within time parameters necessary to insure our compliance with the requirements of the 34 Act, or if the audited financial statements provided do not conform to the representations made by the candidate to be acquired in the closing documents, the closing documents will provide that the proposed transaction will be voidable, at the discretion of our present management. If such transaction is voided, the agreement will also contain a provision providing for the acquisition entity to reimburse us for all costs associated with the proposed transaction.

As of the date of this Report we are engaged in discussions with various companies but there are no assurances that these discussions will result in any definitive agreement. There is no significant material acquisition that is probable to be consummated and there are no assurances that any such acquisition will occur in the future.

We believe there are certain perceived benefits to being a public company whose securities are publicly traded, including the following:

increased visibility in the financial community;

increased valuation;

greater ease in raising capital;

compensation of key employees through stock options for which there may be a market valuation; and

enhanced corporate image.

There are also certain perceived disadvantages to being a trading company including the following:

	·	required publication of corporate information;
	·	required filings of periodic and episodic reports with the Securities and Exchange Commission.

Business entities, if any, which may be interested in a combination with us may include the following:

a company for which a primary purpose of becoming public is the use of its securities for the acquisition of assets or businesses;

a company which is unable to find an underwriter of its securities or is unable to find an underwriter of securities on terms acceptable to it;

a company which wishes to become public with less dilution of its securities than would occur upon an underwriting;

a company which believes that it will be able to obtain investment capital on more favorable terms after it has become public;

a foreign company which may wish an initial entry into the United States securities market;

a special situation company, such as a company seeking a public market to satisfy redemption requirements under a qualified Employee Stock Option Plan;

a company seeking one or more of the other perceived benefits of becoming a public company.

A business combination with a private company will normally involve the transfer to the private company of the majority of our issued and outstanding common stock and the substitution by the private company of its own management and board of directors.

The proposed business activities described herein classify us as a “shell company. The Securities and Exchange Commission and certain states have enacted statutes, rules and regulations regarding the sales of securities of shell companies, as well as limitations on a shareholder’s ability to sell their “restricted” securities. Rule 144 is not available to a shareholder of a shell company unless and until the Company files a registration statement with the SEC that includes certain specific information about existing business operations of a registrant and thereafter must wait an additional one year to take advantage of that exemption from registration.

Rule 12b-2 of the 34 Act defines a shell company as a company that has:

(1) No or nominal operations; and

(2) Either:

(i) No or nominal assets;

(ii) Assets consisting solely of cash and cash equivalents; or

(iii) Assets consisting of any amount of cash and cash equivalents and nominal other assets.

We will continue to file all reports required of us under the Exchange Act until a business combination has occurred, or we organically build our business from cash raised from investors. A business combination will normally result in a change in control and management of our Company. Since a principal benefit of a business combination with us would normally be considered our status as a reporting company, it is anticipated that we will continue to file reports under the Exchange Act following a business combination. No assurance can be given that this will occur or, if it does, for how long.

LIQUIDITY AND CAPITAL RESOURCES

As of December 31, 2016, we had no cash or cash equivalents.

In March 2015, we commenced a private placement of our common stock to accredited investors at $1.50 per share. Through September 30, 2015, we issued an aggregate of 536,334 shares and received $804,500 in gross proceeds.

We have no revenue-producing operations or other source of income as of the date of this Report, nor have we had any revenue during the past 3 years. See “Plan of Operation” above herein for an explanation of our current business activities.

It is our current intention to raise debt and/or equity financing to fund ongoing operating expenses. There is no assurance that these events will be satisfactorily completed or at terms acceptable to us. Any issuance of equity securities, if accomplished, could cause substantial dilution to existing stockholders. Any failure by us to successfully implement these plans would have a material adverse effect on our business, including the possible inability to continue operations.

Subsequent Events – Recent Financings

Also in April 2018, we issued 60,000 shares of our Series A Convertible Preferred Stock at a price of $1.00 per share to our current management, all of whom are accredited investors. Each share of Series A Convertible Preferred Stock is convertible into 1,250 shares of common stock and vote on an as converted basis. The rights and designations of these Preferred Shares include the following:

entitles the holder thereof to 1,250 votes on all matters submitted to a vote of the shareholders;

The holders of outstanding Series A Convertible Preferred Stock shall only be entitled to receive dividends upon declaration by the Board of Directors of a dividend payable on our Common Stock whereupon the holders of the Series A Convertible Preferred Stock shall receive a dividend on the number of shares of Common Stock in to which each share of Series A Convertible Preferred Stock is convertible;

Each Series A Preferred Share is convertible into 1,250 shares of Common Stock; and

not redeemable.

In July 2018, we commenced a private offering of up to $2,000,000 of 12% Convertible Debentures. Each Convertible Debenture is convertible into shares of our common stock at the lesser of $0.40 or a 50% of the closing market price on the date a business combination valued at great than $5,000,000 is completed. See “Part I, Item 1, Business.” To date, we have received $640,000 in subscriptions under this offering. The Convertible Debenture is being offered in reliance upon Rule 506 of Regulation D. We intend to use the proceeds from this offering on working capital.

We must raise additional funds to support our expected operating plan and our continued operations. We cannot provide any assurances that we will be able to raise such funds or whether we would be able to raise such funds on terms that are favorable to us. We may seek to borrow monies from lenders at commercial rates, but such lenders will probably be at higher than bank rates, which higher rates could, depending on the amount borrowed, render the net operating income of any of our planned profitable businesses insufficient to cover the interest burden.

Currently, we have no committed source for any funds as of the date hereof. No representation is made that any funds will be available when needed. In the event funds cannot be raised if and when needed, we may not be able to carry out our business plan and could fail in business as a result of these uncertainties.

Inflation

Although our operations are influenced by general economic conditions, we do not believe that inflation had a material effect on our results of operations during the year ended December 31, 2016.

Critical Accounting Policies and Estimates

Critical Accounting Estimates

Our financial statements and accompanying notes have been prepared in accordance with U.S. GAAP. The preparation of these financial statements requires management to make estimates, judgments and assumptions that affect reported amounts of assets, liabilities, revenues and expenses. We continually evaluate the accounting policies and estimates used to prepare the financial statements. The estimates are based on historical experience and assumptions believed to be reasonable under current facts and circumstances. Actual amounts and results could differ from these estimates made by management. Certain accounting policies that require significant management estimates and are deemed critical to our results of operations or financial position are discussed in our Annual Report on Form 10-K for the year ended December 31, 2014 in the Critical Accounting Policies section of Management’s Discussion and Analysis of Financial Condition and Results of Operations.

RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

On June 10, 2014, the FASB issued update ASU 2014-10, Development Stage Entities (Topic 915). Among other things, the amendments in this update removed the definition of development stage entity from Topic 915, thereby removing the distinction between development stage entities and other reporting entities from U.S. GAAP. In addition, the amendments eliminate the requirements for development stage entities to (1) present inception-to-date information on the statements of income, cash flows and stockholders’ equity, (2) label the financial statements as those of a development stage entity; (3) disclose a description of the development stage activities in which the entity is engaged and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. The amendments are effective for annual reporting periods beginning after December 31, 2014 and interim reporting periods beginning after December 15, 2015. However, entities are permitted to early adopt for any annual or interim reporting period for which the financial statements have yet to be issued. The Company has elected to early adopt these amendments, and accordingly, has not labeled the financial statements as those of a development stage entity and has not presented inception-to-date information on the respective financial statements.

Management has reviewed all other recently issued, but not yet effective, accounting pronouncements and do not believe the future adoption of any such pronouncements may be expected to cause a material impact on our financial condition or the results of our operations.

Off-Balance Sheet Arrangements

We have not entered into any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources and would be considered material to investors.

Item 7a. Quantitative And Qualitative Disclosures About Market Risk

As a smaller reporting company, we are not required to provide this information.

Item 8. Financial Statements And Supplementary Data

The financial statements and supplementary financial information required by this Item are set forth immediately following the signature page and are incorporated herein by reference.

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.

On June 11, 2018, we engaged BF Borgers CPA PC as our independent registered public accounting firm, and effective June 11, 2018, we dismissed KLJ & Associates, LLP (“KLJ”), as our independent registered public accounting firm. The decision to dismiss KLJ and to appoint BF Borgers CPA PC was approved by our board of directors. No audit or audit related services were performed between us and Borgers prior to their appointment.

KLJ’s report on our financial statements for either of the two fiscal years ended December 31, 2014 and 2013 did not contain an adverse opinion or disclaimer of opinion, or qualification or modification as to uncertainty, audit scope, or accounting principles, except that such report on our financial statements contained an explanatory paragraph in respect to the substantial doubt about our ability to continue as a going concern.

During the two fiscal years ended December 31, 2014 and 2013 and in the subsequent interim period through the date of dismissal, there were no disagreements, resolved or not, with KLJ on any matter of accounting principles or practices, financial statement disclosure, or audit scope and procedures, which disagreement(s), if not resolved to the satisfaction of KLJ, would have caused KLJ to make reference to the subject matter of the disagreement(s) in connection with its report. During our two most recent fiscal years ended December 31, 2014 and 2013 and in the subsequent interim period through the date of dismissal, there were no reportable events as described in Item 304(a)(1)(v) of Regulation S-K.

The audit report of KLJ on our financial statements as of and for the years ended December 31, 2014 and 2013 did not contain an adverse opinion or disclaimer of opinion, nor was it qualified or modified as to uncertainty, audit scope, or accounting principles, except relevant to the audit reports for the years ended December 31, 2014 and 2013, which stated as follows:

“The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company, has suffered net losses and has had negative cash flows from operating activities during the years ended December 31, 2014 and 2013. These matters raise substantial doubt about the Company’s ability to continue as a going concern. Management’s plans concerning these matters are also described in Note 2. The financial statements do not include any adjustments to the recoverability and classification of asset carrying amounts or the amount and classification of liabilities that might result should the Company be unable to continue as a going concern.”

Borgers has been retained to audit our financial statement for our fiscal years ending December 31, 2015, 2016 and 2017, and have included the 2015 report as part of this annual report on Form 10-K for our fiscal year ending December 31, 2015.

Item 9A. Controls and Procedures.

Disclosure Controls and Procedures

Disclosure Controls and Procedures–Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) as of the end of the period covered by this Report.

These controls are designed to ensure that information required to be disclosed in the reports we file or submit pursuant to the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission, and that such information is accumulated and communicated to our management, including our CEO/CFO to allow timely decisions regarding required disclosure.

Based on this evaluation, our CEO and CFO have concluded that our disclosure controls and procedures were effective as of December 31, 2016, at reasonable assurance levels.

We believe that our financial statements presented in this annual report on Form 10-K fairly present, in all material respects, our financial position, results of operations, and cash flows for all periods presented herein.

Inherent Limitations – Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. The design of any system of controls is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdown can occur because of simple error or mistake. In particular, many of our current processes rely upon manual reviews and processes to ensure that neither human error nor system weakness has resulted in erroneous reporting of financial data.

Changes in Internal Control over Financial Reporting – There were no changes in our internal control over financial reporting during our fiscal year ended December 31, 2016, which were identified in conjunction with management’s evaluation required by paragraph (d) of Rules 13a-15 and 15d-15 under the Exchange Act, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

This Annual Report does not include an attestation report of our registered public accounting firm regarding internal control over financial reporting. Management’s report was not subject to attestation by our registered public accounting firm pursuant to temporary rules of the Securities and Exchange Commission that permit us to provide only management’s report in this Annual Report.

Management Report on Internal Control over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rule 13a-15(f) or 15d-15(f) promulgated under the Exchange Act. Those rules define internal control over financial reporting as a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that:

	·	Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the Company;
	·	Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and the receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the Company; and
	·	Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisitions, use or disposition of the company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal controls over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Management assessed the effectiveness of our internal control over financial reporting as of December 31, 2016. In making this assessment, our management used the criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).

Based on its assessment, management has concluded that as of December 31, 2016, our disclosure controls and procedures and internal control over financial reporting were ineffective, based in part on the issues discussed above.

Item 9b. Other Information

None.

PART III

Item 10. Directors, Executive Officers and Corporate Governance.

The following table sets forth information concerning management of our Company as of the date of filing of this report.

Name	Age		Position
Dominick Colvin		51	Chief Executive Officer, President, director
Gary Herick		55	Chief Financial Officer, director
Matt Nicosia		44	director
Jim Samuelson		48	director

Dominick Colvin, 51, was appointed as our Chief Executive Officer, President and a director in April 2018. In addition to his positions with our Company, since June 2007 Mr. Colvin has been President of PLC International Investments, Inc., a private held Canadian company engaged in power production, oil and coal mining.

Gary Herick, 55, was appointed as our Chief Financial Officer in April 2018. Since April 2016, he had been our President and CEO, as well as a director, a position he has retained. In addition to his positions with our Company, Mr. Herick has been President of Arrowhead Consulting, LLC, Edwards, Colorado, a general business consulting company. From May 2011 through August 2017 he was also Director of Finance for Hinto Energy Inc., a public reporting company until 2017 that was engaged in the oil and gas industry. In August 2017, a petition to place Hinto Energy in involuntary bankruptcy was filed. As of the date of this report no final adjudication of this matter has occurred.

Matthew Nicosia 44, was appointed as a director of our Company in April 2018. Since November 2006, Mr. Nicosia has also been the Chairman and CEO of Vivakor Inc., a Nevada corporation based in Irvine, CA, whose common stock trades on the OTC Markets, which is an asset acquisition company focused on the natural resources and precious metals industry. In addition, from January 2011 through March 2012, Mr. Nicosia was founder, Chairman and CEO of Regeneca, Inc. a Southern California-based skin care company, which produced consumer, prescription and OTC products distributed through plastic surgeons and dermatologists as well as through retail and other mass-marketing channels. Mr. Nicosia received his Bachelor of Arts degree in International Relations and Portuguese from Brigham Young University in 1997 and an MBA from Pepperdine University in 2002. Mr. Nicosia is fluent in Portuguese and Spanish.

James Samuelson, 48, was appointed as a director of our Company in April 2018. Since June 2017, Mr. Samuelson has served as a consultant to Vivakor, Inc., a Nevada corporation based in Irvine, CA, whose common stock trades on the OTC Markets which is an asset acquisition company focused on the natural resources and precious metals industry. From January 2006 to June 2016, Mr. Samuelson served as CEO and President of Mid-America Renewable Fuels, Inc., a privately held company engaged in the development and acquisition of renewable energy facilities. Prior to 2006, Mr. Samuelson served as the Chief Financial Officer of a publicly traded technology company headquartered in Berlin, Germany and worked as an investment banker in Paris, France and Vienna, Austria. Mr. Samuelson received a B.S.B.A. in 1992 and a MBA in 1996, both from Creighton University.

The following person was our sole director and executive officer as of December 31, 2016.

Name		Age		Position
Gary Herick⁽²⁾		55		Director

Director Independence

During 2016 our Board was composed of one member. As of the date of this Report, it consists of four members. Our Common Stock is not currently listed for trading on a national securities exchange and, as such, we are not subject to any director independence standards. No member of our Board of Directors is considered an independent director. We evaluated independence in accordance with the rules of The New York Stock Exchange, Inc., which generally provides that a director is not independent if: (i) the director is, or in the past three years has been, an employee of ours; (ii) a member of the director’s immediate family is, or in the past three years has been, an executive officer of ours; (iii) the director or a member of the director’s immediate family has received more than $120,000 per year in direct compensation from us other than for service as a director (or for a family member, as a non-executive employee); (iv) the director or a member of the director’s immediate family is, or in the past three years has been, employed in a professional capacity by our independent public accountants, or has worked for such firm in any capacity on our audit; (v) the director or a member of the director’s immediate family is, or in the past three years has been, employed as an executive officer of a company where one of our executive officers serves on the compensation committee; or (vi) the director or a member of the director’s immediate family is an executive officer of a company that makes payments to, or receives payments from, us in an amount which, in any twelve-month period during the past three years, exceeds the greater of $1,000,000 or 2% of that other company’s gross revenues.

Board Committees

As of the date of this report we do not have any committees of our Board of Directors. We expect to form an Audit Committee, a Compensation Committee, a Corporate Governance Committee, and a Nominating Committee in the near future. Thus, there is a potential conflict of interest in that our directors have the authority to determine issues concerning management compensation, in essence their own, and audit issues that may affect management decisions. We are not aware of any other conflicts of interest with any of our executives or directors.

There are no family relationships among any of our officers or directors.

Involvement in Certain Legal Proceedings

To our knowledge, our directors and executive officers have not been involved in any of the following events during the past ten years:

	1.	any bankruptcy petition filed by or against such person or any business of which such person was a general partner or executive officer, with the exception of Gary Herick who served as an officer of Hinto Energy which is subject to an involuntary bankruptcy proceeding, either at the time of the bankruptcy or within two years prior to that time;

	2.	any conviction in a criminal proceeding or being subject to a pending criminal proceeding (excluding traffic violations and other minor offenses);

	3.	being subject to any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction, permanently or temporarily enjoining him from or otherwise limiting his involvement in any type of business, securities or banking activities or to be associated with any person practicing in banking or securities activities;

	4.	being found by a court of competent jurisdiction in a civil action, the SEC or the Commodity Futures Trading Commission to have violated a Federal or state securities or commodities law, and the judgment has not been reversed, suspended, or vacated;

	5.	being subject of, or a party to, any Federal or state judicial or administrative order, judgment decree, or finding, not subsequently reversed, suspended or vacated, relating to an alleged violation of any Federal or state securities or commodities law or regulation, any law or regulation respecting financial institutions or insurance companies, or any law or regulation prohibiting mail or wire fraud or fraud in connection with any business entity; or

	6.	being subject of or party to any sanction or order, not subsequently reversed, suspended, or vacated, of any self-regulatory organization, any registered entity or any equivalent exchange, association, entity or organization that has disciplinary authority over its members or persons associated with a member.

Section 16(a) Beneficial Ownership Reporting Compliance

Section16(a) of the Securities Exchange Act of 1934 (the “34 Act”) requires our officers and directors and persons owning more than ten percent of the Common Stock, to file initial reports of ownership and changes in ownership with the Securities and Exchange Commission (“SEC”). Additionally, Item 405 of Regulation S-K under the 34 Act requires us to identify in our Form 10-K and proxy statement those individuals for whom one of the above referenced reports was not filed on a timely basis during the most recent year or prior years. To the best of our knowledge, all required reports were filed, but filed late. Relevant to our new management, as of the date of this report we are in the process of obtaining the personal codes of new management. Once done all reports are expected to be filed.

CODE OF ETHICS

A code of ethics relates to written standards that are reasonably designed to deter wrongdoing and to promote:

Honest and ethical conduct, including the ethical handling of actual or apparent conflicts of interest between personal and professional relationships;

Full, fair, accurate, timely and understandable disclosure in reports and documents that are filed with, or submitted to, the SEC and in other public communications made by an issuer;

Compliance with applicable governmental laws, rules and regulations;

The prompt internal reporting of violations of the code to an appropriate person or persons identified in the code; and

Accountability for adherence to the code.

In 2014, we adopted a corporate Code of Business Conduct and Ethics (our “Code of Ethics”) that applies to our principal executive officer, principal accounting officer, and all persons performing similar functions, and we distributed this document to all employees then. We now ask all new employees to acknowledge in writing their receipt and understanding of this document as part of the hiring process. Our Code of Ethics is publicly available on our Internet website at http://cannapharmarx.com/wp-content/uploads/2014/12/Business_Code_of_Conduct.pdf.

Item 11. Executive Compensation.

The following table sets forth information concerning all cash and non-cash compensation awarded to, earned by or paid to our CEO and our most highly compensated executive officers in 2016 and 2015. We did not then have an established policy to provide compensation to members of our Board of Directors for their services in that capacity, although we may choose to adopt a policy in the future.

SUMMARY COMPENSATION TABLE

Name and Position

Year

Salary

($)

Bonus

($)

Option
awards
($)⁽¹⁾

All other
compensation
($)

Total

(S)

Gerald E. Crocker, CEO

2016

–

2015

150,000

–

34,476

184,476

Gary Herick, CFO⁽²⁾

2016

92,459

⁽²⁾

–

92,459

2015

77,624

–

77,624

James Smeeding, President ⁽³⁾

2016

50,000

–

50,000

2015

123,886

–

123,886

Mathew Sherwood, VP of R&D ⁽³⁾

2016

50,000

–

50,000

2015

128,829

–

128,829

_______________________

⁽¹⁾

Each of these directors also served as executives and officers with the Company in 2014. As such, each were issued 750,000 options subject to vesting over three years, one-third for each year of service, exercisable at an exercise price of $3.78 per share granted on November 1, 2014. Valuation of options awards was based on Black-Scholes modeling, as discussed in Note 1 to the Company’s financial statements included with this report.

⁽²⁾

Mr. Herick resigned as Chief Financial Officer effective February 9, 2015 and was appointed again as our CFO in April 2016. All of his 2016 compensation has been accrued.

There were no employment or other agreements with our executive officers, and no salaries were paid as such in 2016 and 2015.

Outstanding Equity Awards at Fiscal Year-End

Our officers and directors do not have unexercised options, stock that has not vested, or equity awards. There were no outstanding equity awards to our named executive officers as of December 31, 2016 or 2015.

Mr. Herick was granted stock options to purchase an aggregate of 750,000 common shares at an exercise price of $1.00. These options expire November 1, 2024 if not exercised.

Director Compensation

No compensation was paid to Mr. Herick, the Company’s only director in 2016.

Other than as disclosed herein, our directors did not receive any compensation during the years ended December 31, 2016 and 2015, in consideration for their services rendered in their capacity as directors and no arrangements are presently in place regarding compensation to directors for their services as directors or for committee participation or special assignments. We did not pay any directors fees for meeting attendance.

We do not believe risks arising from our compensation policies and practices for our employees are reasonably likely to have a material adverse effect upon us

Equity Compensation Plans

As of the date of this report, we do not have any equity compensation plan but may adopt one or more in the future.

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.

The following table sets forth certain information regarding the ownership of Common Stock as of the date of this Report, by (i) each person known to us to own more than 5% of our outstanding Common Stock as of the date of this Report, (ii) each of our directors, (iii) each of our executive officers, and (iv) all of our directors and executive officers as a group. Unless otherwise indicated, all shares are owned directly and the indicated person has sole voting and investment power. The address for each Beneficial Owner named is the address of our principal executive office. The percentage of ownership is based upon 17,960,741 Common Shares and 60,000,000 Series A Convertible Preferred Shares issued and outstanding as of the date of this Report.

Title of Class	Name of Beneficial Owner	Amount and Nature Of Beneficial Ownership		Percent Of Class
Common and Series A Preferred	Gary Herick⁽¹⁾ 2 Park Plaza Suite 1200B Irvine, CA 92614		26,166,000		28.1%
Series A Preferred	James Samuelson⁽¹⁾ 2 Park Plaza Suite 1200B Irvine, CA 92614		25,000,000		26.9%
Series A Preferred	Matt Nicosia⁽¹⁾ 2 Park Plaza Suite 1200B Irvine, CA 92614		25,000,000		26.9%
Common and Series A Preferred	All Officers and Directors as a Group (4 person)		76,166,000		81.9%

_______________________

	⁽¹⁾	Officer and/or Director of our Company.
	⁽²⁾	Includes 20,000 shares of Series A Convertible Preferred Share will entitle the holder thereof to 1,250 votes on all matters submitted to a vote of the shareholders.
	⁽³⁾	Includes 826,000 shares of our Common Stock owned by companies owned and controlled by Mr. Herick, as well as family members. Mr. Herick disclaims ownership of 300,000 of these shares.

Item 13. Certain Relationships and Related Transactions, and Director Independence.

On May 9, 2014, Mr. Cutler, our former Officer and a director, to whom we owed $234,981 on a related-party loan, released all claims as to this debt. This loan was retired and settled in the share purchase transaction where CannaRx acquired 9,000,000 shares of our common stock in exchange for $296,000. Mr. Cutler’s interest in this transaction was $146,000. Additionally, on May 9, 2014, CannaRx also acquired 1,421,120 shares directly from Mr. Cutler in exchange for $54,000. In total, on May 9, 2014, Mr. Cutler received $200,000 in full payment of both his related-party loan and for 1,421,120 shares of Golden Dragon Holding Co. During 2014, the largest amount of principal outstanding on the loan was $234,981. The rate of interest payable on the loan was 8%. All related-party debt, including all accrued interest, was relieved in the May 9, 2014 Share Purchase Agreement among Golden Dragon Holding Co, David J. Cutler and CannaRx.

On May 15, 2014, we entered into an Agreement and Plan of Merger (the “Merger Agreement”) with CannaRx and CPHR Acquisition Corp., a newly-formed and wholly owned subsidiary of the Company (“CPHR”), pursuant to which CPHR would be merged with and into CannaRx, resulting in CPHR ceasing its corporate existence and CannaRx becoming a subsidiary of the Company. In light of the Cohen litigation described in Item 3 (Legal Proceedings) of this report, the parties determined to abandon the Merger Agreement.

In the fourth quarter of 2014, we authorized the entrance into an exchange agreement and representations with certain shareholders of CannaRx. The form of that exchange agreement and representations (the “Exchange Agreement”) is attached to this Annual Report on Form 10-K as Exhibit 10.2. Pursuant to the Exchange Agreement, each CannaRx shareholder party agreed to exchange his or her shares of CannaRx on a one-for-one basis in exchange for shares of our Common Stock. The parties subsequently decided to terminate the Exchange Agreement.

As of December 31, 2016 and December 31, 2015, there were no receivable due from related parties. As of December 31, 2016, there was $150,000 due to two former directors, which was accrued salaries arising out of services provided in 2015 and 2016. We are currently in discussions with these individuals to settle this obligation.

Subsequent Events

On April 1, 2018 we changed our principal place of business to 2 Park Plaza, Suite 1200 – B. Irvine, CA 92614. This space is provided to us on a twelve month term by a company to which Mr. Nicosia, one of our directors, serves as Chief Executive Officer. Our monthly rent is $1,000, however, as of the date of this filing, we have not made any rent payments and continue to accrue those amounts as accounts payable.

Item 14. Principal Accounting Fees and Services.

B F Borgers CPA PC was appointed as our independent auditor in June 2018, to audit our financial statements for the fiscal years ended December 31, 2015, 2016 and 2017. The following table reflects the fees paid or accrued to our independent auditor in the years ended December 31, 2015 and 2016:

	December 31, 2016		December 31, 2015
Audit Fees	$	9,500	$	5,000
Tax Fees	$	–	$	–
All Other Fees	$	–	$	–

PART IV

Item 15. Exhibits, Financial Statements Schedules.

The following exhibits are included with this report:

Exhibit Number		Description

31.1		Certification of Chief Executive Officer required by Rule 13a-14(a) under the Exchange Act (filed herewith).

31.2		Certification of Chief Financial Officer required by Rule 13a-14(a) under the Exchange Act (filed herewith).

32		Certification of Principal Executive, Financial and Accounting Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of Sarbanes-Oxley Act of 2002 (filed herewith).

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this Annual Report to be signed on its behalf by the undersigned thereunder duly authorized.

	CANNAPHARMARX, INC.

Dated: September 14, 2018	By:	/s/ Dominic Colvin
		Dominic Colvin, Principal Executive Officer


	By:	/s/ Gary Herick
		Gary Herick, Principal Financial and Accounting Officer

In accordance with the Exchange Act, this Annual Report has been signed below by the following persons on behalf of the registrant and in the capacities indicated on September 14, 2018.

s/ Dominic Colvin

Dominic Colvin, Director

s/ Gary Herick

Gary Herick, Director

s/ Matt Nicosia

Matt Nicosia, Director

s/ James Samuelson

James Samuelson, Director

INDEX TO FINANCIAL STATEMENTS

		Page

Report of Independent Registered Accounting Firm		F-2

Audited Financial Statements:

Balance Sheets as of December 31, 2016 and 2015		F-3

Statements of Operations for the Years ended December 31, 2016 and 2015		F-4

Statement of Changes in Shareholders’ Equity (Deficit) for the years ended December 31, 2016 and 2015		F-5

Statements of Cash Flows for the years ended December 31, 2016 and 2015		F-6

Notes to the Financial Statements		F-7

F-1

Report of Independent Registered Public Accounting Firm

To the shareholders and the board of directors of CannaPharmaRx, Inc.

Opinion on the Financial Statements

We have audited the accompanying balance sheets of CannaPharmaRx, Inc. (the "Company") as of December 31, 2016 and 2015, the related statements of operations, stockholders' equity (deficit), and cash flows for the years then ended, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2016 and 2015, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States.

Basis for Opinion

These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud.

Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.

Substantial Doubt about the Company’s Ability to Continue as a Going Concern

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company’s significant operating losses raise substantial doubt about its ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

/s/ BF Borgers CPA PC

BF Borgers CPA PC

We have served as the Company's auditor since 2018.

Lakewood, CO

September 14, 2018

F-2

CANNAPHARMARX, INC.

BALANCE SHEETS

	December 31,			December 31,
	2016			2015

ASSETS

Current assets
Cash and cash equivalents	$	–		$	2,621
Prepaid expenses		1,667			9,438
Total current assets		1,667			12,059
Total Assets	$	1,667		$	12,059


LIABILITIES & STOCKHOLDERS' DEFICIT

Current liabilities
Accounts payable and accrued expenses	$	599,575		$	456,601
Accrued legal settlement payable in cash		190,000			190,000
Accrued expense - related party		150,000			50,000
Loan payable - related party		19,758			–
Total current liabilities		959,333			696,601
Total Liabilities		959,333			696,601

Stockholders' Equity
Preferred stock, $0.0001 par value, 10,000,000 shares authorized, no shares issued and outstanding		–			–
Common stock, $0.0001 par value; 100,000,000 shares authorized, 17,960,741 and 17,960,741 issued and outstanding as of December 31, 2016 and December 31, 2015, respectively		1,796			1,796
Additional paid in capital		32,930,067			32,201,942
Retained earnings (deficit)		(33,889,530	)		(32,888,280	)
Total Stockholders' Deficit		(957,667	)		(684,542	)
Total Liabilities and Stockholders' Deficit	$	1,667		$	12,059

The accompanying notes are an integral part of these financial statements.

F-3

CANNAPHARMARX, INC.

STATEMENTS OF OPERATIONS

	For the Year
	Ended December 31,
	2016			2015

Revenue	$	–		$	–

Operating Expenses:
General & administrative		276,766			4,217,456
Stock-based compensation		728,125			7,435,004
Total operating expenses		1,004,891			11,652,460
Income (loss) from operations		(1,004,891	)		(11,652,460	)

Other income (expense)
Interest (expense)		(423	)		(2,724	)
Loss on disposal of assets		–			(87,748	)
Other income (expense)		4,064			–
Other income (expense) net		3,641			(90,472	)
Income (loss) before provision for income taxes		(1,001,250	)		(11,742,932	)
Provision (credit) for income tax		–			–
Net income (loss)	$	(1,001,250	)	$	(11,742,932	)

Net income (loss) per share (Basic and fully diluted)	$	(0.06	)	$	(0.77	)

Weighted average number of shares outstanding		17,960,741			15,338,352

The accompanying notes are an integral part of these financial statements.

F-4

CANNAPHARMARX, INC.

STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)

	Common Stock						Paid in			Retained Earnings/			Stockholders' Equity/
	Shares			Value			Capital			(Deficit)			(Deficit)
Balances at December 31, 2014		17,374,407		$	1,737		$	20,855,381		$	(21,145,348	)	$	(288,230	)

Common stock sold		556,334			56			804,496						804,552
Shares issued in acquisition of Canna Colorado		9,750,000			975			(975	)					–
Shares issued to vendor in prior year, paid par this period		–			–			120						120
Cancellation of shares owned by Canna Colorado		(10,420,000	)		(1,042	)		1,042						–
Debt settled in merger/acquisition		–			–			1,245						1,245
Bank refund of overdraft balance to close account		–			–			4,556						4,556
Shares issued in litigation settlement		600,000			60			1,597,440						1,597,500
Warrants issued for IR services		–			–			1,153,643						1,153,643
Shares issued for brokerage services		100,000			10			349,990						350,000
Stock based compensation		–			–			7,435,004						7,435,004
Net loss		–			–			–			(11,742,932	)		(11,742,932	)
Balances at December 31, 2015		17,960,741		$	1,796		$	32,201,942		$	(32,888,280	)	$	(684,542	)

Stock based compensation		–			–			728,125			–			728,125
Net loss											(1,001,250	)		(1,001,250	)
Balances at December 31, 2016		17,960,741		$	1,796		$	32,930,067		$	(33,889,530	)	$	(957,667	)

The accompanying notes are an integral part of these financial statements.

F-5

CANNAPHARMARX, INC.

STATEMENTS OF CASH FLOWS

	For the Year
	Ended December 31,
	2016			2015
Cash Flows From Operating Activities:
Net income (loss)	$	(1,001,250	)	$	(11,742,932	)

Adjustments to reconcile net income to net cash provided by (used for) operating activities
Depreciation		–			12,031
Stock-based compensation expense		728,125			7,435,004
Warrants issued for services		–			1,153,643
Settlement payment non-current portion		–			(135,000	)
Stock issued for services		–			350,000
Legal settlement payable in stock		–			(1,597,500	)
Legal settlement by stock issuance		–			1,597,500
Changes in operating assets and liabilities
Decrease in other receivables		–			531
(Increase)/decrease in prepaid expenses		–			34,133
Increase/(Decrease) in accounts payable and accrued expenses		7,771			319,735
Decrease in current legal settlement payment		142,974			(25,000	)
Increase/(Decrease) in accrued payable - related party		100,000			49,096
Net cash provided by (used for) operating activities		(22,380	)		(2,548,759	)

Cash Flows From Investing Activities:
Purchase of fixed assets		–			(2,078	)
Deposit paid toward specialty Pharma acquisition -recovery		–			50,000
Disposal of assets net of depreciation		–			87,748
Net cash provided by (used for) investing activities		–			135,670

Cash Flows From Financing Activities:
Proceeds from (paydown of) related party loans		19,758			–
Cash forgiveness from bank to close overdrawn account		–			4,556
Cash acquired in acquisition of Canna Colorado		–			1,245
Shares issued to vendor in prior year, paid par this period		–			120
Proceeds from sales of common stock		–			804,550
Net cash provided by (used for) financing activities		19,758			810,471

Net Increase (Decrease) In Cash		(2,621	)		(1,602,618	)
Cash At The Beginning Of The Period		2,621			1,605,239
Cash At The End Of The Period	$	–		$	2,621

Schedule of Non-Cash Investing and Financing Activities
Value of stock issued in litigation settlement	$	–		$	1,597,500

Supplemental Disclosure
Cash paid for interest	$	423		$	2,071
Cash paid for income taxes	$	–		$	500

The accompanying notes are an integral part of these financial statements.

F-6

CANNAPHARMARX, INC.

NOTES TO FINANCIAL STATEMENTS

FOR THE YEARS ENDED DECEMBER 31, 2016 AND 2015

NOTE 1.

NATURE OF OPERATIONS AND SIGNIFICANT ACCOUNTING POLICIES

NATURE OF OPERATIONS

CannaPharmaRx, Inc. (the “Company”) is a Delaware corporation. As of the date of this Report the Company intends to engage in acquisitions or joint ventures with a company or companies that will allow to become a national or internationally branded cannabis cultivation company, or otherwise engage in the cannabis industry. Management is engaged in seeking out and evaluating businesses for acquisition. However, if an opportunity in another industry arises the Company will review that opportunity as well. The proposed business activities described herein classify us as a “shell company. Rule 12b-2 of the 34 Act defines a shell company as a company that has:

(1) No or nominal operations; and

(2) Either:

(i) No or nominal assets;

(ii) Assets consisting solely of cash and cash equivalents; or

(iii) Assets consisting of any amount of cash and cash equivalents and nominal other assets.

HISTORY

The Company was originally incorporated in the State of Colorado in August 1998 under the name “Network Acquisitions, Inc.” It changed its name to Cavion Technologies, Inc. in February 1999 and subsequently to Concord Ventures, Inc. in October 2006. On December 21, 2000, the Company filed for protection under Chapter 11 of the United States Bankruptcy Code. In connection with the filing, on February 16, 2001, the Company sold its entire business, and all of its assets, for the benefit of its creditors. After the sale, the Company still had liabilities of $8.4 million and was subsequently dismissed by the Court from the Chapter 11 reorganization, effective March 13, 2001, at which time the last of the Company’s then remaining directors resigned. On March 13, 2001, the Company had no business or other source of income, no assets, no employees or directors, outstanding liabilities of approximately $8.4 million and had terminated its duty to file reports under securities law. In February 2008, after filing of a Form 10 registration statement pursuant to the Securities Exchange Act of 1934, as amended, we were re-listed on the OTC Bulletin Board.

In April 2010, the Company re-domiciled in Delaware under the name CCVG, Inc. (“CCVG”).Effective December 31, 2010, the Company completed an Agreement and Plan of Merger and Reorganization (the “Reorganization") which provided for the merger of two of the Company’s wholly owned subsidiaries. As a result of this reorganization the Company’s name became “Golden Dragon Inc.,” which became the surviving publicly quoted parent holding company.

On May 9, 2014, the Company entered into a Share Purchase Agreement (the “Share Purchase Agreement”) with CannaPharmaRX, Inc., a Colorado corporation (“Canna Colorado”), and David Cutler, a former President, Chief Executive Officer, Chief Financial Officer and director of the Company. Under the Share Purchase Agreement, Canna Colorado purchased 1,421,120 restricted shares of the Company’s common stock from Mr. Cutler and an additional 9,000,000 common shares directly from the Company.

In October 2014, the Company changed its legal name to “CannaPharmaRx, Inc.”

As a result of the aforesaid transactions, the Company became an early-stage pharmaceutical company whose purpose was to advance cannabinoid research and discovery using proprietary formulation and drug delivery technology then under development.

In April 2016, the Company ceased operations. Its then management resigned their respective positions with the Company, with the exception of Mr. Gary Herick, who remains as an officer and director.

F-7

As a result, the Company is now considered a “shell” company as defined under the Securities Exchange Act of 1934, as amended.

BASIS OF PRESENTATION

The accompanying financial statements have been prepared in accordance with the Financial Accounting Standards Board (“FASB”) “FASB Accounting Standard Codification™” (the “Codification”) which is the source of authoritative accounting principles recognized by the FASB to be applied by nongovernmental entities in the preparation of financial statements in conformity with generally accepted accounting principles (“GAAP”) in the United States. Certain amounts in prior periods have been reclassified to conform to current presentation.

The Company has been inactive since April 2016.

USE OF ESTIMATES

The preparation of our financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in these financial statements and accompanying notes. Actual results could differ from those estimates. Due to uncertainties inherent in the estimation process, it is possible that these estimates could be materially revised within the next year.

CASH AND CASH EQUIVALENTS

Cash and cash equivalents consist of cash and highly liquid debt instruments with original maturities of less than three months.

PROPERTY AND EQUIPMENT

Historically when the company acquired fixed assets, depreciation expenses have been calculated using the straight-line method over the estimated useful lives of the respective assets, ranging from three to seven years.

Depreciation expenses total $-0- and $12,031 for the years ended December 31, 2016 and December 31, 2015, respectively.

DEFERRED COSTS AND OTHER OFFERING COSTS

All costs with respect to raising capital in the two private placements of the Company’s common stock were expensed by the Company both in 2014 and 2015. These costs were applied as internal operational expenses. The Company had no deferred costs or other stock offering costs as of either December 31, 2016 or December 31, 2015.

Future costs associated with raising capital, be it debt or equity, may more likely be incurred as a direct variable cost with third parties. Our intent is to initially defer these costs and ultimately offset them against the proceeds from these capital or financial transactions if successful, or expensed if the proposed financial transaction proves unsuccessful.

IMPAIRMENT OF LONG-LIVED AND INTANGIBLE ASSETS

In the event that facts and circumstances indicated that the cost of long-lived and intangible assets may be impaired, an evaluation of recoverability will be performed. If an evaluation is required, the estimated future undiscounted cash flows associated with the asset will be compared to the asset’s carrying amount to determine if a write-down to market value or discounted cash flow value will be required. The Company had no intangible assets at December 31, 2016, or December 31, 2015.

F-8

FAIR VALUES OF ASSETS AND LIABILITIES

The Company groups its financial assets and financial liabilities generally measured at fair value in three levels, based on the markets in which the assets and liabilities are traded and the reliability of the assumptions used to determine fair value.

		Level 1:		Valuation is based on quoted prices in active markets for identical assets or liabilities. Level 1 assets and liabilities generally include debt and equity securities that are traded in an active exchange market. Valuations are obtained from readily available pricing sources for market transactions involving identical assets or liabilities.

		Level 2:		Valuation is based on observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. For example, Level 2 assets and liabilities may include debt securities with quoted prices that are traded less frequently than exchange-traded instruments.

		Level 3:		Valuation is based on unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Level 3 assets and liabilities include financial instruments whose value is determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation. This category generally includes certain private equity investments and long-term derivative contracts.

The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. As of December 31, 2016 and December 31, 2015, the Company does not have any assets or liabilities which are considered Level 2 or 3 in the hierarchy.

The Company may also be required, from time to time, to measure certain other financial assets at fair value on a nonrecurring basis. These adjustments to fair value usually result from application of lower-of-cost-or-market accounting or write-downs of individual assets. There were no such adjustments in the periods ended December 31, 2016, or December 31, 2015.

FINANCIAL INSTRUMENTS

The estimated fair value for financial instruments was determined at discrete points in time based on relevant market information. These estimates involved uncertainties and could not be determined with exact precision. The fair value of the Company’s financial instruments, which include cash, prepaid expenses, accounts payable and the related party loan, each approximate their carrying value due either to their short length to maturity or interest rates that approximate prevailing market rates.

INCOME TAXES

The Company accounts for income taxes under the liability method, which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statements and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.

COMPREHENSIVE INCOME (LOSS)

Comprehensive income is defined as all changes in stockholders’ equity (deficit), exclusive of transactions with owners, such as capital investments. Comprehensive income includes net income or loss, changes in certain assets and liabilities that are reported directly in equity such as translation adjustments on investments in foreign subsidiaries and unrealized gains (losses) on available-for-sale securities. From our inception, there have been no differences between our comprehensive loss and net loss.

F-9

INCOME (LOSS) PER SHARE

Income (loss) per share is presented in accordance with Accounting Standards Update (“ASU”), Earning per Share (Topic 260) which requires the presentation of both basic and diluted earnings per share (“EPS”) on the income statements. Basic EPS would exclude any dilutive effects of options, warrants and convertible securities but does include the restricted shares of common stock issued. Diluted EPS reflects the potential dilution that would occur if securities or other contracts to issue common stock were exercised or converted to common stock. Basic EPS calculations are determined by dividing net income by the weighted average number of shares of common stock outstanding during the year. Diluted EPS calculations are determined by dividing net income by the weighted average number of common shares and dilutive common share equivalents outstanding.

Stock options outstanding at December 31, 2016 to purchase 750,000 shares of common stock are excluded from the calculations of diluted net loss per share since their effect is antidilutive.

STOCK-BASED COMPENSATION

The Company has adopted ASC Topic 718, (Compensation—Stock Compensation), which establishes a fair value method of accounting for stock-based compensation plans. In accordance with guidance now incorporated in ASC Topic 718, the cost of stock options and warrants issued to employees and non-employees is measured on the grant date based on the fair value. The fair value is determined using the Black-Scholes option pricing model. The resulting amount is charged to expense on the straight-line basis over the period in which the Company expects to receive the benefit, which is generally the vesting period. The fair value of stock warrants was determined at the date of grant using the Black-Scholes option pricing model. The Black-Scholes option model requires management to make various estimates and assumptions, including expected term, expected volatility, risk-free rate and dividend yield.

BUSINESS SEGMENTS

Our activities during the year ended December 31, 2016 comprised a single segment.

RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

NOTE 2.

GOING CONCERN AND LIQUIDITY

The Company had $-0- cash on hand as of December 31, 2016, and no revenue-producing business or other sources of income. Additionally, as of December 31, 2016, the Company had outstanding liabilities totaling $959,333 and stockholders’ deficit of $957,667. The Company had a working capital deficit of $957,667 at December 31, 2016.

F-10

In the Company’s financial statements for the fiscal years ended December 31, 2016 and 2015, the Reports of the Independent Registered Public Accounting Firm include an explanatory paragraph that describes substantial doubt about our ability to continue as a going concern. These financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. Based on our current financial projections, we believe we do not have sufficient existing cash resources to fund our current limited operations.

It is the Company’s current intention to raise debt and/or equity financing to fund ongoing operating expenses. There is no assurance that these events will be satisfactorily completed or at terms acceptable to the Company. Any issuance of equity securities, if accomplished, could cause substantial dilution to existing stockholders. Any failure by the Company to successfully implement these plans would have a material adverse effect on its business, including the possible inability to continue operations.

NOTE 3.

ASSETS

As of December 31, 2016, the Company had $1,667 in total assets comprised of prepaid expenses.

NOTE 4.

ACCOUNTS PAYABLE AND ACCRUED EXPENSES

As of December 31, 2016, the balance of accounts payable and accrued expenses was $769,333, which is primarily comprised of trade payables and accrued salaries and wages and legal fees.

Additionally, accrued legal settlements payable in cash over the next 12 months total $190,000 as of December 31, 2016, as discussed in Note 6 (Litigation and Accrued Settlement Liabilities).

NOTE 5.

COMMITMENTS

OPERATING LEASE

The Company had a non-cancellable operating lease for its headquarters located in Carneys Point, New Jersey. The term of this lease ended April 30, 2016. As of December 31, 2016 the Company owed $18,540 on this lease and had not made any new commitments for office space.

NOTE 6.

LITIGATION AND ACCRUED SETTLEMENT LIABILITIES

On October 30, 2014, Gary M. Cohen (“Cohen”), former President, Chief Operating Officer and a board member of Canna Colorado, filed a lawsuit against Canna Colorado and an individual officer and board member, Gary Herick, who is currently an officer and director of the Company. On November 26, 2014, Cohen filed an amended complaint naming the Company and Gerald Crocker, James Smeeding, Robert Liess and Mathew Sherwood, each of whom was a member of the Company’s board of directors at that time, as defendants. In his amended complaint, Cohen alleged various employment- related contract and wrongful termination claims, as well as claims alleging breach of fiduciary duty, misappropriation of assets, violations of corporate law regarding his access to internal corporate information, and alleged violations of U.S. federal securities laws, the Sarbanes- Oxley Act of 2002 and the U.S. Internal Revenue Code. Cohen’s claims arose out of the removal of Cohen as an officer and board member of Canna Colorado, which occurred on or about October 23, 2014. The defendants successfully removed Cohen’s lawsuit from state court in Hillsborough County, Florida—where it was filed originally—to the U.S. District Court in Tampa, Florida.

On November 11, 2014, the Company, under its former name Golden Dragon Holding Co., sued Cohen in U.S. District Court in New Jersey for libel and tortious interference.

F-11

On March 30, 2015, the Company executed a Confidential Settlement and Release of Claims Agreement dated March 30, 2015, by and between the Company, Canna Colorado, Cohen and the other individuals named above (the “Settlement Agreement”). Pursuant to the terms of the Settlement Agreement, the lawsuit filed in Florida on October 30, 2014 against the Company, Canna Colorado, Herick, Crocker, Smeeding, Sherwood and Liess by Cohen has been resolved and dismissed. The parties amicably resolved their differences before any discovery occurred or before any decision by the court on the merits of any claims. The Company and all the individuals who had been sued categorically denied of all Mr. Cohen’s claims and allegations, maintained that the allegations were false and were prepared to assert counterclaims of their own. As part of the parties’ resolution, Cohen retracted his allegations.

As part of the Settlement Agreement, the Company agreed to purchase all of Mr. Cohen’s 2,250,000 shares of Canna Colorado for a purchase price of $350,000, with $85,000 payable up front and the remainder payable in equal installments of $15,000 per month over the next 17 months, and a payment of $10,000 in the eighteenth month. In addition, on May 4, 2015, the Company issued 600,000 unregistered restricted shares of its common stock to Mr. Cohen as part of the Settlement Agreement. The Company valued those shares at $1,597,500 based on the trading average of the Company’s stock over the ten days preceding entry into the Settlement Agreement and recorded an expense in such amount during the period ended December 31, 2014. Pursuant to the Settlement Agreement, $160,000 has been paid to Mr. Cohen in cash through September 30, 2015 in accordance with the settlement payment terms, leaving a remaining liability of $190,000 as of December 31, 2015 to be paid in cash in the future, since no payments were made subsequent to September 30, 2015.

In addition, the Company and Cohen have resolved their differences in the Company’s lawsuit filed against Cohen on November 11, 2014 in New Jersey. The Company has dismissed its claims against Cohen of libel and tortious interference.

NOTE 7.

STOCKHOLDERS’ EQUITY

PREFERRED STOCK

The Company is authorized to issue up to 10,000,000 shares of one or more series of preferred stock, at a par value of $0.0001, all of which is nonvoting. The Board of Directors may, without stockholder approval, determine the dividend rates, redemption prices, preferences on liquidation or dissolution, conversion rights, voting rights and any other preferences. No shares of preferred stock were issued or outstanding as of December 31, 2016.

COMMON STOCK

The Company is authorized to issue 100,000,000 shares of common stock, par value $0.0001 per share. As of December 31, 2016, 17,960,741 shares of common stock were issued and outstanding.

RECENT ISSUANCES OF COMMON STOCK

In March 2015, the Company began offering in a private placement of shares of its restricted common stock to accredited investors at $1.50 per share (the “Private Placement”). Through December 31, 2015 the Company issued a total of 556,334 shares in exchange for $804,550 of gross proceeds.

On June 25, 2015, the Company issued 100,000 shares of the Company’s common stock to Benjamin & Jerold Brokerage I, LLC, an Illinois limited liability company (“B&J”), which had provided advisory and capital raising services to the Company. These shares were expensed to stock-based compensation costs during the period and were valued at $350,000 based on the trading average of the Company’s stock over the ten days preceding issuance of those shares.

WARRANTS

On January 20, 2015, the Company issued a 3-year warrant (the “First Warrant”) to Viridian Capital & Research, LLC (“VCR”) as compensation for the services rendered by VCR in connection with the delivery of a company report describing the business, technology and products, markets, growth strategy and financial aspects of the Company. The First Warrant is exercisable for 244,283 of the Company’s fully-diluted common shares at an exercise price equal to the price per share of the Company’s common stock on the 10 days preceding January 20, 2015 or $2.90. The First Warrant has a 3-year life, a cashless exercise provision and is fully transferable with the Company’s approval, which may not be unreasonably withheld. The First Warrant is callable on 60 days’ notice if (i) the Company’s common stock trades on the NASDAQ and (ii) the Company’s common stock trades at three times the exercise price of the First Warrant for 20 consecutive trading days. These warrants were valued at $630,067 using the Black-Scholes method of valuation.

F-12

On February 23, 2015, the Company issued another 3-year warrant (the “Second Warrant,” and together with the First Warrant, the “VCR Warrants”) to VCR as compensation for VCR’s services in managing and implementing investor relations strategies with the U.S. investment community and industry. The Second Warrant is exercisable for 244,283 of the Company’s fully-diluted common shares at an exercise price equal to the price per share of the Company’s common stock on the 10 days preceding February 23, 2015 or $2.50. The Second Warrant has a 3-year life, a cashless exercise provision and is fully transferable with the Company’s approval, which may not be unreasonably withheld. The Second Warrant is callable on 60 days’ notice if (i) the Company’s common stock trades on the NASDAQ and (ii) the Company’s common stock trades at three times the exercise price of the Second Warrant for 20 consecutive trading days. These warrants were valued at $523,576 using the Black-Scholes method of valuation. The Company has not issued any warrants since February 23^rd, 2015.

STOCK OPTIONS

As a result of all stock option activity to date, the Company has recorded aggregate stock-based compensation charges of $728,125 for the year ended December 31, 2016 and $7,435,004 during the year ended December 31, 2015. As of December 31, 2016, 750,000 vested options were outstanding, all of which belonged to Mr. Herick and all had been fully expensed.

NOTE 8.

INCOME TAXES

As of December 31, 2016, the Company has approximately $6,322,000 of federal net operating loss carryforwards, respectively. The federal net operating loss carryforwards begin to expire in 2030. State net operating loss carryforwards begin to expire in 2034. Due to the change in ownership provisions of the Internal Revenue Code, the availability of the Company’s net operating loss carry forwards could be subject to annual limitations against taxable income in future periods, which could substantially limit the eventual utilization of such carry forwards. The Company has not analyzed the historical or potential impact of its equity financings on beneficial ownership and therefore no determination has been made whether the net operating loss carry forward is subject to any Internal Revenue Code Section 382 limitation. To the extent there is a limitation, there could be a substantial reduction in the deferred tax asset with an offsetting reduction in the valuation allowance. As of September 30, 2016, the Company has no unrecognized income tax benefits.

The tax years from 2014 and forward remain open to examination by federal and state authorities due to net operating loss and credit carryforwards. The Company is currently not under examination by the Internal Revenue Service or any other taxing authorities.

NOTE 9. SUBSEQUENT EVENTS

In April 2018, the Company issued 60,000 shares of its Series A Convertible Preferred Stock at $1.00 per share to its current management, all of whom are accredited investors. Each share of Series A Convertible Preferred Stock is convertible into 1,250 shares of common stock and vote on an as converted basis. The rights and designations of these Preferred Shares include the following:

entitles the holder thereof to 1,250 votes on all matters submitted to a vote of the shareholders;

Each Series A Preferred Share is convertible into 1,250 shares of Common Stock;

not redeemable.

In July 2018, the Company commenced an offering of up to $2MM of convertible notes. The notes carry an interest rate of 12% and are convertible into shares of the Company’s common stock at the lesser of $0.40 or 50% discount to the market price on the date of conversion. The term of the notes is for one year and they must be converted upon closing a financing, acquisition or other form of business combination in an amount greater than $5 million. As of the date of this report the Company has accepted aggregate subscriptions of $640,000 in this Offering, none of which has been converted. The offering remains open as of the date of this Report.

On April 1, 2018, the Company changed its principal place of business to 2 Park Plaza, Suite 1200 – B. Irvine, CA 92614. This space is provided on a twelve month term by a company to which Mr. Nicosia, one of the Company’s directors, serves as Chief Executive Officer. Monthly rent is $1,000, however, as of the date of this filing the Company has not made any rent payments and continue to accrue those amounts as accounts payable.

F-13

EX-31.1 2 cannapharmarx_10k-ex3101.htm CERTIFICATION

Exhibit 31.1

CERTIFICATION PURSUANT TO

18 USC, SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES OXLEY ACT OF 2002

I, Nick Colvin, certify that:

I have reviewed this annual report on Form 10-K of Cannapharmarx, Inc.;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedure to be designed under our supervision, to ensure that material information relating to the registrant is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based upon such evaluation; and

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: September 14, 2018	/s/ Dominic Colvin
	Dominic Colvin , Chief Executive Officer

EX-31.2 3 cannapharmarx_10k-ex3102.htm CERTIFICATION

Exhibit 31.2

CERTIFICATION PURSUANT TO

18 USC, SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES OXLEY ACT OF 2002

I, Gary Herick, certify that:

I have reviewed this annual report on Form 10-K of Cannapharmarx, Inc..;

Designed such disclosure controls and procedures, or caused such disclosure controls and procedure to be designed under our supervision, to ensure that material information relating to the registrant, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: September 14, 2018	/s/ Gary Herick
	Gary Herick, Chief Financial Officer

EX-32 4 cannapharmarx_10k-ex3200.htm CERTIFICATION

Exhibit 32

CERTIFICATION PURSUANT TO

18 USC, SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with this annual report of Cannapharmarx Inc. (the “Company”) on Form 10-K for the fiscal year ended December 31, 2016, as filed with the Securities and Exchange Commission on September 14, 2018 (the “Report”), we, the undersigned, in the capacities and on the date indicated below, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of our knowledge:

The Report fully complies with the requirements of Rule 13(a) or 15(d) of the Securities Exchange Act of 1934; and

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: September 14, 2018	/s/ Dominick Colvin
	Dominick Colvin, Chief Executive Officer

Dated: September 14, 2018	/s/ Gary Herick
	Gary Herick, Chief Financial Officer

EX-101.INS 5 cpmd-20161231.xml XBRL INSTANCE FILE 0001081938 2016-01-01 2016-12-31 0001081938 2018-09-13 0001081938 2016-12-31 0001081938 2015-12-31 0001081938 2015-01-01 2015-12-31 0001081938 us-gaap:CommonStockMember 2015-01-01 2015-12-31 0001081938 us-gaap:CommonStockMember 2016-01-01 2016-12-31 0001081938 us-gaap:CommonStockMember 2014-12-31 0001081938 us-gaap:CommonStockMember 2015-12-31 0001081938 us-gaap:CommonStockMember 2016-12-31 0001081938 us-gaap:AdditionalPaidInCapitalMember 2015-01-01 2015-12-31 0001081938 us-gaap:AdditionalPaidInCapitalMember 2016-01-01 2016-12-31 0001081938 us-gaap:AdditionalPaidInCapitalMember 2014-12-31 0001081938 us-gaap:AdditionalPaidInCapitalMember 2015-12-31 0001081938 us-gaap:AdditionalPaidInCapitalMember 2016-12-31 0001081938 us-gaap:RetainedEarningsMember 2015-01-01 2015-12-31 0001081938 us-gaap:RetainedEarningsMember 2016-01-01 2016-12-31 0001081938 us-gaap:RetainedEarningsMember 2014-12-31 0001081938 us-gaap:RetainedEarningsMember 2015-12-31 0001081938 us-gaap:RetainedEarningsMember 2016-12-31 0001081938 2014-12-31 0001081938 us-gaap:StockOptionMember 2016-01-01 2016-12-31 0001081938 us-gaap:StockOptionMember 2016-12-31 0001081938 cpmd:FinancialServicesMember 2015-01-01 2015-12-31 0001081938 us-gaap:StockOptionMember 2015-12-31 0001081938 us-gaap:PrivatePlacementMember 2015-01-01 2015-12-31 0001081938 us-gaap:WarrantMember cpmd:FirstWarrantMember 2015-01-01 2015-12-31 0001081938 us-gaap:WarrantMember cpmd:SecondWarrantMember 2015-01-01 2015-12-31 0001081938 us-gaap:WarrantMember cpmd:FirstWarrantMember 2015-12-31 0001081938 us-gaap:WarrantMember cpmd:SecondWarrantMember 2015-12-31 0001081938 cpmd:NewJerseyMember 2016-01-01 2016-12-31 0001081938 2016-06-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure CannaPharmaRX, Inc. 0001081938 10-K 2016-12-31 false --12-31 No No No Smaller Reporting Company FY 2016 8397371 17960741

190000

-957667

-684542

1737

1796

20855381

32201942

32930067

-21145348

-32888280

-33889530

-288230

-1001250

-11742932

-1001250

17374407

17960741

9750000

975

-975

1245

556334

728125

7435004

728125

120 120 120 120

10420000

1042

-1042

4556 4556 4556

600000

1597500

1597440

1153643

100000

350000

349990

350000

804550

750000

-957667

769333

18540

2016-04-30

244283

2.90

2.50

P3Y

630067 523576

728125

7435004

6322000

2030-12-31

2034-12-31

1667

9438

1667

12059

1667

12059

599575

456601

150000

50000

959333

696601

959333

696601

1796

32930067

32201942

-33889530

-32888280

1667

12059

0.0001

10000000

0.0001

100000000

17960741

276766

4217456

1004891

11652460

423

2724

-87748

3641

-90472

-1001250

-11742932

-0.06

-0.77

17960741

15338352

1153643

350000

135000

0 1597500 0 1597500

-531

-34133

7771

319735

100000

49096

142974 -25000

-22380

-2548759

2078

87748

-50000

135670

19758

0 1245 0 120 0 4556

19758

810471

-2621

-1602618

0 1597500

423

2071

500

2621

1605239

19758

728125

7435004

-1004891

-11652460

4064

804552

804496

12031

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 10%">NOTE 1.</td> <td style="width: 90%">NATURE OF OPERATIONS AND SIGNIFICANT ACCOUNTING POLICIES </td></tr> </table>   NATURE OF OPERATIONS   CannaPharmaRx, Inc. (the “Company”) is a Delaware corporation. As of the date of this Report the Company intends to engage in acquisitions or joint ventures with a company or companies that will allow to become a national or internationally branded cannabis cultivation company, or otherwise engage in the cannabis industry. Management is engaged in seeking out and evaluating businesses for acquisition. However, if an opportunity in another industry arises the Company will review that opportunity as well. The proposed business activities described herein classify us as a “shell company. Rule 12b-2 of the 34 Act defines a shell company as a company that has:   (1) No or nominal operations; and (2) Either: (i) No or nominal assets; (ii) Assets consisting solely of cash and cash equivalents; or (iii) Assets consisting of any amount of cash and cash equivalents and nominal other assets.   HISTORY    The Company was originally incorporated in the State of Colorado in August 1998 under the name “Network Acquisitions, Inc.” It changed its name to Cavion Technologies, Inc. in February 1999 and subsequently to Concord Ventures, Inc. in October 2006. On December 21, 2000, the Company filed for protection under Chapter 11 of the United States Bankruptcy Code. In connection with the filing, on February 16, 2001, the Company sold its entire business, and all of its assets, for the benefit of its creditors. After the sale, the Company still had liabilities of $8.4 million and was subsequently dismissed by the Court from the Chapter 11 reorganization, effective March 13, 2001, at which time the last of the Company’s then remaining directors resigned. On March 13, 2001, the Company had no business or other source of income, no assets, no employees or directors, outstanding liabilities of approximately $8.4 million and had terminated its duty to file reports under securities law. In February 2008, after filing of a Form 10 registration statement pursuant to the Securities Exchange Act of 1934, as amended, we were re-listed on the OTC Bulletin Board.   In April 2010, the Company re-domiciled in Delaware under the name CCVG, Inc. (“CCVG”).Effective December 31, 2010, the Company completed an Agreement and Plan of Merger and Reorganization (the “Reorganization") which provided for the merger of two of the Company’s wholly owned subsidiaries. As a result of this reorganization the Company’s name became “Golden Dragon Inc.,” which became the surviving publicly quoted parent holding company.   On May 9, 2014, the Company entered into a Share Purchase Agreement (the “Share Purchase Agreement”) with CannaPharmaRX, Inc., a Colorado corporation (“Canna Colorado”), and David Cutler, a former President, Chief Executive Officer, Chief Financial Officer and director of the Company. Under the Share Purchase Agreement, Canna Colorado purchased 1,421,120 restricted shares of the Company’s common stock from Mr. Cutler and an additional 9,000,000 common shares directly from the Company.   In October 2014, the Company changed its legal name to “CannaPharmaRx, Inc.”   As a result of the aforesaid transactions, the Company became an early-stage pharmaceutical company whose purpose was to advance cannabinoid research and discovery using proprietary formulation and drug delivery technology then under development.   In April 2016, the Company ceased operations. Its then management resigned their respective positions with the Company, with the exception of Mr. Gary Herick, who remains as an officer and director.   As a result, the Company is now considered a “shell” company as defined under the Securities Exchange Act of 1934, as amended.   BASIS OF PRESENTATION   The accompanying financial statements have been prepared in accordance with the Financial Accounting Standards Board (“FASB”) “FASB Accounting Standard Codification™” (the “Codification”) which is the source of authoritative accounting principles recognized by the FASB to be applied by nongovernmental entities in the preparation of financial statements in conformity with generally accepted accounting principles (“GAAP”) in the United States. Certain amounts in prior periods have been reclassified to conform to current presentation.   The Company has been inactive since April 2016.   USE OF ESTIMATES   The preparation of our financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in these financial statements and accompanying notes. Actual results could differ from those estimates. Due to uncertainties inherent in the estimation process, it is possible that these estimates could be materially revised within the next year.   CASH AND CASH EQUIVALENTS   Cash and cash equivalents consist of cash and highly liquid debt instruments with original maturities of less than three months.   PROPERTY AND EQUIPMENT   Historically when the company acquired fixed assets, depreciation expenses have been calculated using the straight-line method over the estimated useful lives of the respective assets, ranging from three to seven years.   Depreciation expenses total $-0- and $12,031 for the years ended December 31, 2016 and December 31, 2015, respectively.   DEFERRED COSTS AND OTHER OFFERING COSTS   All costs with respect to raising capital in the two private placements of the Company’s common stock were expensed by the Company both in 2014 and 2015. These costs were applied as internal operational expenses. The Company had no deferred costs or other stock offering costs as of either December 31, 2016 or December 31, 2015.   Future costs associated with raising capital, be it debt or equity, may more likely be incurred as a direct variable cost with third parties. Our intent is to initially defer these costs and ultimately offset them against the proceeds from these capital or financial transactions if successful, or expensed if the proposed financial transaction proves unsuccessful.   IMPAIRMENT OF LONG-LIVED AND INTANGIBLE ASSETS   In the event that facts and circumstances indicated that the cost of long-lived and intangible assets may be impaired, an evaluation of recoverability will be performed. If an evaluation is required, the estimated future undiscounted cash flows associated with the asset will be compared to the asset’s carrying amount to determine if a write-down to market value or discounted cash flow value will be required. The Company had no intangible assets at December 31, 2016, or December 31, 2015.   FAIR VALUES OF ASSETS AND LIABILITIES   The Company groups its financial assets and financial liabilities generally measured at fair value in three levels, based on the markets in which the assets and liabilities are traded and the reliability of the assumptions used to determine fair value.   <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr> <td style="vertical-align: top; width: 3%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="white-space: nowrap; vertical-align: top; width: 7%">Level 1:</td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: top; width: 88%; text-align: justify">Valuation is based on quoted prices in active markets for identical assets or liabilities. Level 1 assets and liabilities generally include debt and equity securities that are traded in an active exchange market. Valuations are obtained from readily available pricing sources for market transactions involving identical assets or liabilities.</td></tr> <tr> <td> </td> <td colspan="2"> </td> <td colspan="2"> </td></tr> <tr> <td style="vertical-align: top"> </td> <td style="vertical-align: bottom"> </td> <td style="white-space: nowrap; vertical-align: top">Level 2:</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: top; text-align: justify">Valuation is based on observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. For example, Level 2 assets and liabilities may include debt securities with quoted prices that are traded less frequently than exchange-traded instruments.</td></tr> <tr> <td> </td> <td colspan="2"> </td> <td colspan="2"> </td></tr> <tr> <td style="vertical-align: top"> </td> <td style="vertical-align: bottom"> </td> <td style="white-space: nowrap; vertical-align: top">Level 3:</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: top; text-align: justify">Valuation is based on unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Level 3 assets and liabilities include financial instruments whose value is determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation. This category generally includes certain private equity investments and long-term derivative contracts.</td></tr> </table>   The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. As of December 31, 2016 and December 31, 2015, the Company does not have any assets or liabilities which are considered Level 2 or 3 in the hierarchy.   The Company may also be required, from time to time, to measure certain other financial assets at fair value on a nonrecurring basis. These adjustments to fair value usually result from application of lower-of-cost-or-market accounting or write-downs of individual assets. There were no such adjustments in the periods ended December 31, 2016, or December 31, 2015.   FINANCIAL INSTRUMENTS   The estimated fair value for financial instruments was determined at discrete points in time based on relevant market information. These estimates involved uncertainties and could not be determined with exact precision. The fair value of the Company’s financial instruments, which include cash, prepaid expenses, accounts payable and the related party loan, each approximate their carrying value due either to their short length to maturity or interest rates that approximate prevailing market rates.   INCOME TAXES   The Company accounts for income taxes under the liability method, which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statements and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.   COMPREHENSIVE INCOME (LOSS)   Comprehensive income is defined as all changes in stockholders’ equity (deficit), exclusive of transactions with owners, such as capital investments. Comprehensive income includes net income or loss, changes in certain assets and liabilities that are reported directly in equity such as translation adjustments on investments in foreign subsidiaries and unrealized gains (losses) on available-for-sale securities. From our inception, there have been no differences between our comprehensive loss and net loss.   INCOME (LOSS) PER SHARE   Income (loss) per share is presented in accordance with Accounting Standards Update (“ASU”), Earning per Share (Topic 260) which requires the presentation of both basic and diluted earnings per share (“EPS”) on the income statements. Basic EPS would exclude any dilutive effects of options, warrants and convertible securities but does include the restricted shares of common stock issued. Diluted EPS reflects the potential dilution that would occur if securities or other contracts to issue common stock were exercised or converted to common stock. Basic EPS calculations are determined by dividing net income by the weighted average number of shares of common stock outstanding during the year. Diluted EPS calculations are determined by dividing net income by the weighted average number of common shares and dilutive common share equivalents outstanding.   Stock options outstanding at December 31, 2016 to purchase 750,000 shares of common stock are excluded from the calculations of diluted net loss per share since their effect is antidilutive.   STOCK-BASED COMPENSATION   The Company has adopted ASC Topic 718, (Compensation—Stock Compensation), which establishes a fair value method of accounting for stock-based compensation plans. In accordance with guidance now incorporated in ASC Topic 718, the cost of stock options and warrants issued to employees and non-employees is measured on the grant date based on the fair value. The fair value is determined using the Black-Scholes option pricing model. The resulting amount is charged to expense on the straight-line basis over the period in which the Company expects to receive the benefit, which is generally the vesting period. The fair value of stock warrants was determined at the date of grant using the Black-Scholes option pricing model. The Black-Scholes option model requires management to make various estimates and assumptions, including expected term, expected volatility, risk-free rate and dividend yield.   BUSINESS SEGMENTS   Our activities during the year ended December 31, 2016 comprised a single segment.   RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS   On June 10, 2014, the FASB issued update ASU 2014-10, Development Stage Entities (Topic 915). Among other things, the amendments in this update removed the definition of development stage entity from Topic 915, thereby removing the distinction between development stage entities and other reporting entities from U.S. GAAP. In addition, the amendments eliminate the requirements for development stage entities to (1) present inception-to-date information on the statements of income, cash flows and stockholders’ equity, (2) label the financial statements as those of a development stage entity; (3) disclose a description of the development stage activities in which the entity is engaged and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. The amendments are effective for annual reporting periods beginning after December 31, 2014 and interim reporting periods beginning after December 15, 2015. However, entities are permitted to early adopt for any annual or interim reporting period for which the financial statements have yet to be issued. The Company has elected to early adopt these amendments, and accordingly, has not labeled the financial statements as those of a development stage entity and has not presented inception-to-date information on the respective financial statements.   Management has reviewed all other recently issued, but not yet effective, accounting pronouncements and do not believe the future adoption of any such pronouncements may be expected to cause a material impact on our financial condition or the results of our operations.

FAIR VALUES OF ASSETS AND LIABILITIES   The Company groups its financial assets and financial liabilities generally measured at fair value in three levels, based on the markets in which the assets and liabilities are traded and the reliability of the assumptions used to determine fair value.   <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr> <td style="vertical-align: top; width: 3%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="white-space: nowrap; vertical-align: top; width: 7%">Level 1:</td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: top; width: 88%; text-align: justify">Valuation is based on quoted prices in active markets for identical assets or liabilities. Level 1 assets and liabilities generally include debt and equity securities that are traded in an active exchange market. Valuations are obtained from readily available pricing sources for market transactions involving identical assets or liabilities.</td></tr> <tr> <td> </td> <td colspan="2"> </td> <td colspan="2"> </td></tr> <tr> <td style="vertical-align: top"> </td> <td style="vertical-align: bottom"> </td> <td style="white-space: nowrap; vertical-align: top">Level 2:</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: top; text-align: justify">Valuation is based on observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. For example, Level 2 assets and liabilities may include debt securities with quoted prices that are traded less frequently than exchange-traded instruments.</td></tr> <tr> <td> </td> <td colspan="2"> </td> <td colspan="2"> </td></tr> <tr> <td style="vertical-align: top"> </td> <td style="vertical-align: bottom"> </td> <td style="white-space: nowrap; vertical-align: top">Level 3:</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: top; text-align: justify">Valuation is based on unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Level 3 assets and liabilities include financial instruments whose value is determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation. This category generally includes certain private equity investments and long-term derivative contracts.</td></tr> </table>   The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. As of December 31, 2016 and December 31, 2015, the Company does not have any assets or liabilities which are considered Level 2 or 3 in the hierarchy.   The Company may also be required, from time to time, to measure certain other financial assets at fair value on a nonrecurring basis. These adjustments to fair value usually result from application of lower-of-cost-or-market accounting or write-downs of individual assets. There were no such adjustments in the periods ended December 31, 2016, or December 31, 2015.

BUSINESS SEGMENTS   Our activities during the year ended December 31, 2016 comprised a single segment.

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 10%">NOTE 6.</td> <td>LITIGATION AND ACCRUED SETTLEMENT LIABILITIES </td></tr> </table>   On October 30, 2014, Gary M. Cohen (“Cohen”), former President, Chief Operating Officer and a board member of Canna Colorado, filed a lawsuit against Canna Colorado and an individual officer and board member, Gary Herick, who is currently an officer and director of the Company. On November 26, 2014, Cohen filed an amended complaint naming the Company and Gerald Crocker, James Smeeding, Robert Liess and Mathew Sherwood, each of whom was a member of the Company’s board of directors at that time, as defendants. In his amended complaint, Cohen alleged various employment- related contract and wrongful termination claims, as well as claims alleging breach of fiduciary duty, misappropriation of assets, violations of corporate law regarding his access to internal corporate information, and alleged violations of U.S. federal securities laws, the Sarbanes- Oxley Act of 2002 and the U.S. Internal Revenue Code. Cohen’s claims arose out of the removal of Cohen as an officer and board member of Canna Colorado, which occurred on or about October 23, 2014. The defendants successfully removed Cohen’s lawsuit from state court in Hillsborough County, Florida—where it was filed originally—to the U.S. District Court in Tampa, Florida.   On November 11, 2014, the Company, under its former name Golden Dragon Holding Co., sued Cohen in U.S. District Court in New Jersey for libel and tortious interference.   On March 30, 2015, the Company executed a Confidential Settlement and Release of Claims Agreement dated March 30, 2015, by and between the Company, Canna Colorado, Cohen and the other individuals named above (the “Settlement Agreement”). Pursuant to the terms of the Settlement Agreement, the lawsuit filed in Florida on October 30, 2014 against the Company, Canna Colorado, Herick, Crocker, Smeeding, Sherwood and Liess by Cohen has been resolved and dismissed. The parties amicably resolved their differences before any discovery occurred or before any decision by the court on the merits of any claims. The Company and all the individuals who had been sued categorically denied of all Mr. Cohen’s claims and allegations, maintained that the allegations were false and were prepared to assert counterclaims of their own. As part of the parties’ resolution, Cohen retracted his allegations.   As part of the Settlement Agreement, the Company agreed to purchase all of Mr. Cohen’s 2,250,000 shares of Canna Colorado for a purchase price of $350,000, with $85,000 payable up front and the remainder payable in equal installments of $15,000 per month over the next 17 months, and a payment of $10,000 in the eighteenth month. In addition, on May 4, 2015, the Company issued 600,000 unregistered restricted shares of its common stock to Mr. Cohen as part of the Settlement Agreement. The Company valued those shares at $1,597,500 based on the trading average of the Company’s stock over the ten days preceding entry into the Settlement Agreement and recorded an expense in such amount during the period ended December 31, 2014. Pursuant to the Settlement Agreement, $160,000 has been paid to Mr. Cohen in cash through September 30, 2015 in accordance with the settlement payment terms, leaving a remaining liability of $190,000 as of December 31, 2015 to be paid in cash in the future, since no payments were made subsequent to September 30, 2015.   In addition, the Company and Cohen have resolved their differences in the Company’s lawsuit filed against Cohen on November 11, 2014 in New Jersey. The Company has dismissed its claims against Cohen of libel and tortious interference.

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 10%">NOTE 7.</td> <td>STOCKHOLDERS’ EQUITY </td></tr> </table>   PREFERRED STOCK   The Company is authorized to issue up to 10,000,000 shares of one or more series of preferred stock, at a par value of $0.0001, all of which is nonvoting. The Board of Directors may, without stockholder approval, determine the dividend rates, redemption prices, preferences on liquidation or dissolution, conversion rights, voting rights and any other preferences. No shares of preferred stock were issued or outstanding as of December 31, 2016.   COMMON STOCK   The Company is authorized to issue 100,000,000 shares of common stock, par value $0.0001 per share. As of December 31, 2016, 17,960,741 shares of common stock were issued and outstanding.   RECENT ISSUANCES OF COMMON STOCK   In March 2015, the Company began offering in a private placement of shares of its restricted common stock to accredited investors at $1.50 per share (the “Private Placement”). Through December 31, 2015 the Company issued a total of 556,334 shares in exchange for $804,550 of gross proceeds.   On June 25, 2015, the Company issued 100,000 shares of the Company’s common stock to Benjamin & Jerold Brokerage I, LLC, an Illinois limited liability company (“B&J”), which had provided advisory and capital raising services to the Company. These shares were expensed to stock-based compensation costs during the period and were valued at $350,000 based on the trading average of the Company’s stock over the ten days preceding issuance of those shares.   WARRANTS   On January 20, 2015, the Company issued a 3-year warrant (the “First Warrant”) to Viridian Capital & Research, LLC (“VCR”) as compensation for the services rendered by VCR in connection with the delivery of a company report describing the business, technology and products, markets, growth strategy and financial aspects of the Company. The First Warrant is exercisable for 244,283 of the Company’s fully-diluted common shares at an exercise price equal to the price per share of the Company’s common stock on the 10 days preceding January 20, 2015 or $2.90. The First Warrant has a 3-year life, a cashless exercise provision and is fully transferable with the Company’s approval, which may not be unreasonably withheld. The First Warrant is callable on 60 days’ notice if (i) the Company’s common stock trades on the NASDAQ and (ii) the Company’s common stock trades at three times the exercise price of the First Warrant for 20 consecutive trading days. These warrants were valued at $630,067 using the Black-Scholes method of valuation.   On February 23, 2015, the Company issued another 3-year warrant (the “Second Warrant,” and together with the First Warrant, the “VCR Warrants”) to VCR as compensation for VCR’s services in managing and implementing investor relations strategies with the U.S. investment community and industry. The Second Warrant is exercisable for 244,283 of the Company’s fully-diluted common shares at an exercise price equal to the price per share of the Company’s common stock on the 10 days preceding February 23, 2015 or $2.50. The Second Warrant has a 3-year life, a cashless exercise provision and is fully transferable with the Company’s approval, which may not be unreasonably withheld. The Second Warrant is callable on 60 days’ notice if (i) the Company’s common stock trades on the NASDAQ and (ii) the Company’s common stock trades at three times the exercise price of the Second Warrant for 20 consecutive trading days. These warrants were valued at $523,576 using the Black-Scholes method of valuation. The Company has not issued any warrants since February 23rd, 2015.   STOCK OPTIONS   As a result of all stock option activity to date, the Company has recorded aggregate stock-based compensation charges of $728,125 for the year ended December 31, 2016 and $7,435,004 during the year ended December 31, 2015. As of December 31, 2016, 750,000 vested options were outstanding, all of which belonged to Mr. Herick and all had been fully expensed.

NOTE 9. SUBSEQUENT EVENTS   In April 2018, the Company issued 60,000 shares of its Series A Convertible Preferred Stock at $1.00 per share to its current management, all of whom are accredited investors. Each share of Series A Convertible Preferred Stock is convertible into 1,250 shares of common stock and vote on an as converted basis. The rights and designations of these Preferred Shares include the following:   <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px">·</td> <td style="text-align: justify">entitles the holder thereof to 1,250 votes on all matters submitted to a vote of the shareholders;</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px">·</td> <td style="text-align: justify">The holders of outstanding Series A Convertible Preferred Stock shall only be entitled to receive dividends upon declaration by the Board of Directors of a dividend payable on our Common Stock whereupon the holders of the Series A Convertible Preferred Stock shall receive a dividend on the number of shares of Common Stock in to which each share of Series A Convertible Preferred Stock is convertible;</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px">·</td> <td style="text-align: justify">Each Series A Preferred Share is convertible into 1,250 shares of Common Stock;</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px">·</td> <td style="text-align: justify">not redeemable.</td></tr> </table>   In July 2018, the Company commenced an offering of up to $2MM of convertible notes. The notes carry an interest rate of 12% and are convertible into shares of the Company’s common stock at the lesser of $0.40 or 50% discount to the market price on the date of conversion. The term of the notes is for one year and they must be converted upon closing a financing, acquisition or other form of business combination in an amount greater than $5 million. As of the date of this report the Company has accepted aggregate subscriptions of $640,000 in this Offering, none of which has been converted. The offering remains open as of the date of this Report.   On April 1, 2018, the Company changed its principal place of business to 2 Park Plaza, Suite 1200 – B. Irvine, CA 92614. This space is provided on a twelve month term by a company to which Mr. Nicosia, one of the Company’s directors, serves as Chief Executive Officer. Monthly rent is $1,000, however, as of the date of this filing the Company has not made any rent payments and continue to accrue those amounts as accounts payable.

EX-101.SCH 6 cpmd-20161231.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Statement of Operations link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Statement of Stockholder's Equity link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Statement of Cash Flows link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - 1. Nature of Operations and Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - 2. Going Concern and Liquidity link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - 3. Assets link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - 4. Accounts Payable and Accrued Expenses link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - 5. Commitments link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - 6. Litigation and Accrued Settlement Liabilities link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - 7. Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - 8. Income Taxes link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - 9. Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - 1. Nature of Operations and Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - 1. Nature of Operations and Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - 2. Going Concern and Liquidity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - 3. Assets (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - 4. Accounts Payable and Accrued Expenses (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - 5. Commitments (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - 7. Stockholders' Equity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - 8. Income Taxes (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 cpmd-20161231_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 cpmd-20161231_def.xml XBRL DEFINITION FILE EX-101.LAB 9 cpmd-20161231_lab.xml XBRL LABEL FILE Equity Components [Axis] Common Stock Additional Paid-In Capital Retained Earnings / Accumulated Deficit Antidilutive Securities [Axis] Options [Member] Award Type [Axis] Counterparty Name [Axis] Financial Services Firm [Member] Sale of Stock [Axis] Private Placement [Member] Warrants [Member] Transaction Type [Axis] First Warrant [Member] Second Warrant [Member] Income Tax Authority [Axis] New Jersey [Member] Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Is Entity a Well-known Seasoned Issuer? Is Entity a Voluntary Filer? Is Entity's Reporting Status Current? Entity Filer Category Entity Public Float Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] ASSETS Current assets Cash and cash equivalents Prepaid expenses Total current assets Total Assets LIABILITIES & STOCKHOLDERS' DEFICIT Current liabilities Accounts payable and accrued expenses Accrued legal settlement payable in cash - current portion Accrued legal settlement payable in stock Accrued expense - related party Loan payable - related party Total current liabilities Total Liabilities Stockholders' Equity Preferred stock, $0.0001 par value, 10,000,000 shares authorized, no shares issued and outstanding Common stock, $0.0001 par value; 100,000,000 shares authorized, 17,960,741 issued and outstanding Additional paid in capital Retained deficit Total Stockholders' Deficit Total Liabilities and Stockholders' Deficit Preferred shares, par value Preferred shares, authorized Preferred shares, issued Preferred shares, outstanding Common stock, par value Common stock, authorized Common stock, issued Common stock, outstanding Income Statement [Abstract] Revenue Operating Expenses: General & administrative Stock based compensation Total Operating Expenses Income (loss) from operations Other income (expense) Interest (expense) Loss on disposal of assets Interest income Other income (expense) Other income (expense) net Income (loss) before provision for income taxes Provision (credit) for income tax Net income (loss) Net income (loss) per share - (Basic and fully diluted) Weighted average of shares outstanding Statement [Table] Statement [Line Items] Beginning balance, shares Beginning balance, value Stock issued for acquisition, shares Stock issued for acquisition, value Shares issued to vendor in prior year, paid par this period Cancellation of shares owned by Canna Colorado, shares Cancellation of shares owned by Canna Colorado, value Debt settled in sale/merger/acquisition Bank refund of overdraft balance to close account Shares issued in litigation settlement, shares Shares issued in litigation settlement, value Warrants issued for IR services Shares issued for brokerage services, shares Shares issued for brokerage services, value Common stock sold, shares Common stock sold, value Stock based compensation Net loss Ending balance, shares Ending balance, value Statement of Cash Flows [Abstract] Cash Flows From Operating Activities: Net income (loss) Adjustments to reconcile net income to net cash provided by (used for) operating activities Depreciation Stock-based compensation expense Warrants issued for services Stock issued for services Noncash write-off of related party loan Settlement payment - non-current portion Legal settlement payable in stock Legal settlement by stock issuance Changes in operating Assets & Liabilities Decrease in other receivable (Increase)/decrease in prepaid expenses Increase/(Decrease) in accounts payable and accrued expenses Increase/(Decrease) in accrued payable - related party Increase/(Decrease) in current legal settlement payable Net cash provided by (used for) operating activities Cash Flows From Investing Activities: Purchase of fixed assets Disposal of assets net of depreciation Deposit paid toward Specialty Pharmacy acquisition Net cash provided by (used for) investing activities Cash Flows From Financing Activities: Proceeds from (paydown of) related party loans Debt released in acquisition of Canna Colorado Shares issued to vendor in prior year, paid par this period Cash from bank to close overdrawn account Proceeds from sales of common stock Net cash provided by financing activities Net Increase (Decrease) In Cash and Cash Equivalents Cash and Cash Equivalents At The Beginning Of The Period Cash and Cash Equivalents At The End Of The Period Schedule of Non-Cash Investing and Financing Activities Value of stock issued in litigation settlement Supplemental Disclosure Cash paid for interest Cash paid for income taxes Accounting Policies [Abstract] Nature of Operations and Significant Accounting Policies Organization, Consolidation and Presentation of Financial Statements [Abstract] Going Concern and Liquidity Assets Assets Payables and Accruals [Abstract] Accounts Payable and Accrued Expenses Commitments and Contingencies Disclosure [Abstract] Commitments Litigation and Accrued Settlement Liabilities Equity [Abstract] Stockholders' Equity Income Tax Disclosure [Abstract] Income Taxes Subsequent Events [Abstract] Subsequent Events BASIS OF PRESENTATION USE OF ESTIMATES CASH AND CASH EQUIVALENTS PROPERTY AND EQUIPMENT DEFERRED COSTS AND OTHER OFFERING COSTS IMPAIRMENT OF LONG-LIVED AND INTANGIBLE ASSETS FAIR VALUES OF ASSETS AND LIABILITIES FINANCIAL INSTRUMENTS INCOME TAXES COMPREHENSIVE INCOME (LOSS) INCOME (LOSS) PER SHARE STOCK-BASED COMPENSATION BUSINESS SEGMENTS RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS Depreciation expense Intangible assets Asset impairment charges Antidilutive shares Cash Liabilities Stockholders' Deficit Working Capital Total current assets Total accounts payable and accrued expenses Accrued legal settlements Lease commitment Lease expiration date Stock issued new, shares Proceeds from sale of stock Warrants issued Warrant exercise price Warrant weighted average life Warrant fair value Options outstanding Stock based compensation not yet recognized Net operating loss carryforwards Operating loss carryforward begining expiration date Accrued legal settlement payable in stock Shares issued to vendor in prior year, paid par this period Bank refund of overdraft balance to close account Legal settlement payable in stock Legal settlement by stock issuance Increase/(Decrease) in current legal settlement payable EX-101.PRE 10 cpmd-20161231_pre.xml XBRL PRESENTATION FILE XML 11 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - USD ($)	12 Months Ended
Document and Entity Information - USD ($)	Dec. 31, 2016	Sep. 13, 2018	Jun. 30, 2016
Document And Entity Information
Entity Registrant Name	CannaPharmaRX, Inc.
Entity Central Index Key	0001081938
Document Type	10-K
Document Period End Date	Dec. 31, 2016
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	No
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 8,397,371
Entity Common Stock, Shares Outstanding		17,960,741
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2016

XML 12 R2.htm IDEA: XBRL DOCUMENT

Balance Sheets - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Current assets
Cash and cash equivalents	$ 0	$ 2,621
Prepaid expenses	1,667	9,438
Total current assets	1,667	12,059
Total Assets	1,667	12,059
Current liabilities
Accounts payable and accrued expenses	599,575	456,601
Accrued legal settlement payable in cash - current portion	190,000	190,000
Accrued legal settlement payable in stock		0
Accrued expense - related party	150,000	50,000
Loan payable - related party	19,758	0
Total current liabilities	959,333	696,601
Total Liabilities	959,333	696,601
Stockholders' Equity
Preferred stock, $0.0001 par value, 10,000,000 shares authorized, no shares issued and outstanding	0	0
Common stock, $0.0001 par value; 100,000,000 shares authorized, 17,960,741 issued and outstanding	1,796	1,796
Additional paid in capital	32,930,067	32,201,942
Retained deficit	(33,889,530)	(32,888,280)
Total Stockholders' Deficit	(957,667)	(684,542)
Total Liabilities and Stockholders' Deficit	$ 1,667	$ 12,059

XML 13 R3.htm IDEA: XBRL DOCUMENT

Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2016	Dec. 31, 2015
Statement of Financial Position [Abstract]
Preferred shares, par value	$ 0.0001	$ 0.0001
Preferred shares, authorized	10,000,000	10,000,000
Preferred shares, issued	0	0
Preferred shares, outstanding	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, authorized	100,000,000	100,000,000
Common stock, issued	17,960,741	17,960,741
Common stock, outstanding	17,960,741	17,960,741

XML 14 R4.htm IDEA: XBRL DOCUMENT

Statement of Operations - USD ($)	12 Months Ended
Statement of Operations - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Income Statement [Abstract]
Revenue	$ 0	$ 0
Operating Expenses:
General & administrative	276,766	4,217,456
Stock based compensation	728,125	7,435,004
Total Operating Expenses	1,004,891	11,652,460
Income (loss) from operations	(1,004,891)	(11,652,460)
Other income (expense)
Interest (expense)	(423)	(2,724)
Loss on disposal of assets	0	(87,748)
Interest income		0
Other income (expense)	4,064	0
Other income (expense) net	3,641	(90,472)
Income (loss) before provision for income taxes	(1,001,250)	(11,742,932)
Provision (credit) for income tax	0	0
Net income (loss)	$ (1,001,250)	$ (11,742,932)
Net income (loss) per share - (Basic and fully diluted)	$ (0.06)	$ (0.77)
Weighted average of shares outstanding	17,960,741	15,338,352

XML 15 R5.htm IDEA: XBRL DOCUMENT

Statement of Stockholder's Equity - USD ($)	Common Stock	Additional Paid-In Capital	Retained Earnings / Accumulated Deficit	Total
Beginning balance, shares at Dec. 31, 2014	17,374,407
Beginning balance, value at Dec. 31, 2014	$ 1,737	$ 20,855,381	$ (21,145,348)	$ (288,230)
Stock issued for acquisition, shares	9,750,000
Stock issued for acquisition, value	$ 975	(975)
Shares issued to vendor in prior year, paid par this period		120		120
Cancellation of shares owned by Canna Colorado, shares	(10,420,000)
Cancellation of shares owned by Canna Colorado, value	$ (1,042)	1,042
Debt settled in sale/merger/acquisition		1,245
Bank refund of overdraft balance to close account		4,556
Shares issued in litigation settlement, shares	600,000
Shares issued in litigation settlement, value	$ 60	1,597,440		1,597,500
Warrants issued for IR services		1,153,643		1,153,643
Shares issued for brokerage services, shares	100,000
Shares issued for brokerage services, value	$ 10	349,990		350,000
Common stock sold, shares	556,334
Common stock sold, value	$ 56	804,496		804,552
Stock based compensation		7,435,004		7,435,004
Net loss			(11,742,932)	(11,742,932)
Ending balance, shares at Dec. 31, 2015	17,960,741
Ending balance, value at Dec. 31, 2015	$ 1,796	32,201,942	(32,888,280)	(684,542)
Stock issued for acquisition, shares	9,750,000
Stock issued for acquisition, value	$ 975	(975)
Shares issued to vendor in prior year, paid par this period		120		120
Cancellation of shares owned by Canna Colorado, shares	(10,420,000)
Cancellation of shares owned by Canna Colorado, value	$ (1,042)	1,042
Debt settled in sale/merger/acquisition		1,245		1,245
Bank refund of overdraft balance to close account		4,556		4,556
Shares issued in litigation settlement, shares	600,000
Shares issued in litigation settlement, value	$ 60	1,597,440		1,597,500
Warrants issued for IR services		1,153,643		1,153,643
Shares issued for brokerage services, shares	100,000
Shares issued for brokerage services, value	$ 10	349,990		350,000
Stock based compensation		728,125		728,125
Net loss			(1,001,250)	(1,001,250)
Ending balance, shares at Dec. 31, 2016	17,960,741
Ending balance, value at Dec. 31, 2016	$ 1,796	$ 32,930,067	$ (33,889,530)	$ (957,667)

XML 16 R6.htm IDEA: XBRL DOCUMENT

Statement of Cash Flows - USD ($)	12 Months Ended
Statement of Cash Flows - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Cash Flows From Operating Activities:
Net income (loss)	$ (1,001,250)	$ (11,742,932)
Adjustments to reconcile net income to net cash provided by (used for) operating activities
Depreciation	0	12,031
Stock-based compensation expense	728,125	7,435,004
Warrants issued for services	0	1,153,643
Stock issued for services	0	350,000
Noncash write-off of related party loan		0
Settlement payment - non-current portion	0	(135,000)
Legal settlement payable in stock	0	(1,597,500)
Legal settlement by stock issuance	0	1,597,500
Changes in operating Assets & Liabilities
Decrease in other receivable	0	531
(Increase)/decrease in prepaid expenses	0	34,133
Increase/(Decrease) in accounts payable and accrued expenses	7,771	319,735
Increase/(Decrease) in accrued payable - related party	100,000	49,096
Increase/(Decrease) in current legal settlement payable	142,974	(25,000)
Net cash provided by (used for) operating activities	(22,380)	(2,548,759)
Cash Flows From Investing Activities:
Purchase of fixed assets	0	(2,078)
Disposal of assets net of depreciation	0	87,748
Deposit paid toward Specialty Pharmacy acquisition	0	50,000
Net cash provided by (used for) investing activities	0	135,670
Cash Flows From Financing Activities:
Proceeds from (paydown of) related party loans	19,758	0
Debt released in acquisition of Canna Colorado	0	1,245
Shares issued to vendor in prior year, paid par this period	0	120
Cash from bank to close overdrawn account	0	4,556
Proceeds from sales of common stock	0	804,550
Net cash provided by financing activities	19,758	810,471
Net Increase (Decrease) In Cash and Cash Equivalents	(2,621)	(1,602,618)
Cash and Cash Equivalents At The Beginning Of The Period	2,621	1,605,239
Cash and Cash Equivalents At The End Of The Period	0	2,621
Schedule of Non-Cash Investing and Financing Activities
Value of stock issued in litigation settlement	0	1,597,500
Supplemental Disclosure
Cash paid for interest	423	2,071
Cash paid for income taxes	$ 0	$ 500

XML 17 R7.htm IDEA: XBRL DOCUMENT

1. Nature of Operations and Significant Accounting Policies

12 Months Ended

Dec. 31, 2016

Accounting Policies [Abstract]

Nature of Operations and Significant Accounting Policies

NOTE 1.

NATURE OF OPERATIONS AND SIGNIFICANT ACCOUNTING POLICIES

NATURE OF OPERATIONS

(1) No or nominal operations; and

(2) Either:

(i) No or nominal assets;

(ii) Assets consisting solely of cash and cash equivalents; or

(iii) Assets consisting of any amount of cash and cash equivalents and nominal other assets.

HISTORY

In October 2014, the Company changed its legal name to “CannaPharmaRx, Inc.”

In April 2016, the Company ceased operations. Its then management resigned their respective positions with the Company, with the exception of Mr. Gary Herick, who remains as an officer and director.

As a result, the Company is now considered a “shell” company as defined under the Securities Exchange Act of 1934, as amended.

BASIS OF PRESENTATION

The Company has been inactive since April 2016.

USE OF ESTIMATES

CASH AND CASH EQUIVALENTS

Cash and cash equivalents consist of cash and highly liquid debt instruments with original maturities of less than three months.

PROPERTY AND EQUIPMENT

Depreciation expenses total $-0- and $12,031 for the years ended December 31, 2016 and December 31, 2015, respectively.

DEFERRED COSTS AND OTHER OFFERING COSTS

IMPAIRMENT OF LONG-LIVED AND INTANGIBLE ASSETS

FAIR VALUES OF ASSETS AND LIABILITIES

		Level 1:		Valuation is based on quoted prices in active markets for identical assets or liabilities. Level 1 assets and liabilities generally include debt and equity securities that are traded in an active exchange market. Valuations are obtained from readily available pricing sources for market transactions involving identical assets or liabilities.

		Level 2:		Valuation is based on observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. For example, Level 2 assets and liabilities may include debt securities with quoted prices that are traded less frequently than exchange-traded instruments.

		Level 3:		Valuation is based on unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Level 3 assets and liabilities include financial instruments whose value is determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation. This category generally includes certain private equity investments and long-term derivative contracts.

FINANCIAL INSTRUMENTS

INCOME TAXES

COMPREHENSIVE INCOME (LOSS)

INCOME (LOSS) PER SHARE

Stock options outstanding at December 31, 2016 to purchase 750,000 shares of common stock are excluded from the calculations of diluted net loss per share since their effect is antidilutive.

STOCK-BASED COMPENSATION

BUSINESS SEGMENTS

Our activities during the year ended December 31, 2016 comprised a single segment.

RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

XML 18 R8.htm IDEA: XBRL DOCUMENT

2. Going Concern and Liquidity

12 Months Ended

Dec. 31, 2016

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Going Concern and Liquidity

NOTE 2.

GOING CONCERN AND LIQUIDITY

XML 19 R9.htm IDEA: XBRL DOCUMENT

3. Assets

12 Months Ended

Dec. 31, 2016

Assets

Assets

NOTE 3.

ASSETS

As of December 31, 2016, the Company had $1,667 in total assets comprised of prepaid expenses.

XML 20 R10.htm IDEA: XBRL DOCUMENT

4. Accounts Payable and Accrued Expenses

12 Months Ended

Dec. 31, 2016

Payables and Accruals [Abstract]

Accounts Payable and Accrued Expenses

NOTE 4.

ACCOUNTS PAYABLE AND ACCRUED EXPENSES

As of December 31, 2016, the balance of accounts payable and accrued expenses was $769,333, which is primarily comprised of trade payables and accrued salaries and wages and legal fees.

Additionally, accrued legal settlements payable in cash over the next 12 months total $190,000 as of December 31, 2016, as discussed in Note 6 (Litigation and Accrued Settlement Liabilities).

XML 21 R11.htm IDEA: XBRL DOCUMENT

5. Commitments

12 Months Ended

Dec. 31, 2016

Commitments and Contingencies Disclosure [Abstract]

Commitments

NOTE 5.

COMMITMENTS

OPERATING LEASE

XML 22 R12.htm IDEA: XBRL DOCUMENT

6. Litigation and Accrued Settlement Liabilities

12 Months Ended

Dec. 31, 2016

Commitments and Contingencies Disclosure [Abstract]

Litigation and Accrued Settlement Liabilities

NOTE 6.

LITIGATION AND ACCRUED SETTLEMENT LIABILITIES

On November 11, 2014, the Company, under its former name Golden Dragon Holding Co., sued Cohen in U.S. District Court in New Jersey for libel and tortious interference.

XML 23 R13.htm IDEA: XBRL DOCUMENT

7. Stockholders' Equity

12 Months Ended

Dec. 31, 2016

Equity [Abstract]

Stockholders' Equity

NOTE 7.

STOCKHOLDERS’ EQUITY

PREFERRED STOCK

COMMON STOCK

The Company is authorized to issue 100,000,000 shares of common stock, par value $0.0001 per share. As of December 31, 2016, 17,960,741 shares of common stock were issued and outstanding.

RECENT ISSUANCES OF COMMON STOCK

WARRANTS

STOCK OPTIONS

XML 24 R14.htm IDEA: XBRL DOCUMENT

8. Income Taxes

12 Months Ended

Dec. 31, 2016

Income Tax Disclosure [Abstract]

Income Taxes

NOTE 8.

INCOME TAXES

XML 25 R15.htm IDEA: XBRL DOCUMENT

9. Subsequent Events

12 Months Ended

Dec. 31, 2016

Subsequent Events [Abstract]

Subsequent Events

NOTE 9. SUBSEQUENT EVENTS

entitles the holder thereof to 1,250 votes on all matters submitted to a vote of the shareholders;

Each Series A Preferred Share is convertible into 1,250 shares of Common Stock;

not redeemable.

XML 26 R16.htm IDEA: XBRL DOCUMENT

1. Nature of Operations and Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2016

Accounting Policies [Abstract]

BASIS OF PRESENTATION

The Company has been inactive since April 2016.

USE OF ESTIMATES

CASH AND CASH EQUIVALENTS

Cash and cash equivalents consist of cash and highly liquid debt instruments with original maturities of less than three months.

PROPERTY AND EQUIPMENT

Depreciation expenses total $-0- and $12,031 for the years ended December 31, 2016 and December 31, 2015, respectively.

DEFERRED COSTS AND OTHER OFFERING COSTS

IMPAIRMENT OF LONG-LIVED AND INTANGIBLE ASSETS

FAIR VALUES OF ASSETS AND LIABILITIES

		Level 1:		Valuation is based on quoted prices in active markets for identical assets or liabilities. Level 1 assets and liabilities generally include debt and equity securities that are traded in an active exchange market. Valuations are obtained from readily available pricing sources for market transactions involving identical assets or liabilities.

		Level 2:		Valuation is based on observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. For example, Level 2 assets and liabilities may include debt securities with quoted prices that are traded less frequently than exchange-traded instruments.

		Level 3:		Valuation is based on unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Level 3 assets and liabilities include financial instruments whose value is determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation. This category generally includes certain private equity investments and long-term derivative contracts.

FINANCIAL INSTRUMENTS

INCOME TAXES

COMPREHENSIVE INCOME (LOSS)

INCOME (LOSS) PER SHARE

Stock options outstanding at December 31, 2016 to purchase 750,000 shares of common stock are excluded from the calculations of diluted net loss per share since their effect is antidilutive.

STOCK-BASED COMPENSATION

BUSINESS SEGMENTS

Our activities during the year ended December 31, 2016 comprised a single segment.

RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

XML 27 R17.htm IDEA: XBRL DOCUMENT

1. Nature of Operations and Significant Accounting Policies (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Depreciation expense	$ 0	$ 12,031
Intangible assets	0	0
Asset impairment charges	$ 0	$ 0
Options [Member]
Antidilutive shares	750,000

XML 28 R18.htm IDEA: XBRL DOCUMENT

2. Going Concern and Liquidity (Details Narrative) - USD ($)	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash	$ 0	$ 2,621	$ 1,605,239
Liabilities	959,333	696,601
Stockholders' Deficit	(957,667)	$ (684,542)	$ (288,230)
Working Capital	$ (957,667)

XML 29 R19.htm IDEA: XBRL DOCUMENT

3. Assets (Details Narrative) - USD ($)	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Assets
Cash and cash equivalents	$ 0	$ 2,621	$ 1,605,239
Prepaid expenses	1,667	9,438
Total current assets	$ 1,667	$ 12,059

XML 30 R20.htm IDEA: XBRL DOCUMENT

4. Accounts Payable and Accrued Expenses (Details Narrative) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Payables and Accruals [Abstract]
Total accounts payable and accrued expenses	$ 769,333
Accrued legal settlements	$ 190,000	$ 190,000

XML 31 R21.htm IDEA: XBRL DOCUMENT

5. Commitments (Details Narrative)	12 Months Ended
5. Commitments (Details Narrative)	Dec. 31, 2016 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Lease commitment	$ 18,540
Lease expiration date	Apr. 30, 2016

XML 32 R22.htm IDEA: XBRL DOCUMENT

7. Stockholders' Equity (Details Narrative) - USD ($)	12 Months Ended
7. Stockholders' Equity (Details Narrative) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Proceeds from sale of stock	$ 0	$ 804,550
Shares issued for brokerage services, value	350,000	350,000
Stock based compensation	$ 728,125	$ 7,435,004
Warrants [Member] \| First Warrant [Member]
Warrants issued		244,283
Warrant exercise price		$ 2.90
Warrant weighted average life		3 years
Warrant fair value		$ 630,067
Warrants [Member] \| Second Warrant [Member]
Warrants issued		244,283
Warrant exercise price		$ 2.50
Warrant weighted average life		3 years
Warrant fair value		$ 523,576
Options [Member]
Options outstanding	750,000	0
Stock based compensation not yet recognized	$ 728,125	$ 7,435,004
Financial Services Firm [Member]
Shares issued for brokerage services, shares		100,000
Shares issued for brokerage services, value		$ 350,000
Private Placement [Member]
Stock issued new, shares		556,334
Proceeds from sale of stock		$ 804,550

XML 33 R23.htm IDEA: XBRL DOCUMENT

8. Income Taxes (Details Narrative)	12 Months Ended
8. Income Taxes (Details Narrative)	Dec. 31, 2016 USD ($)
Net operating loss carryforwards	$ 6,322,000
Operating loss carryforward begining expiration date	Dec. 31, 2030
New Jersey [Member]
Operating loss carryforward begining expiration date	Dec. 31, 2034

EXCEL 34 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 35 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 36 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 38 FilingSummary.xml IDEA: XBRL DOCUMENT 3.10.0.1 html 32 135 1 false 11 0 false 4 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://cannapharmarx.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Balance Sheets Sheet http://cannapharmarx.com/role/BalanceSheets Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Balance Sheets (Parenthetical) Sheet http://cannapharmarx.com/role/BalanceSheetsParenthetical Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Statement of Operations Sheet http://cannapharmarx.com/role/StatementOfOperations Statement of Operations Statements 4 false false R5.htm 00000005 - Statement - Statement of Stockholder's Equity Sheet http://cannapharmarx.com/role/StatementOfStockholdersEquity Statement of Stockholder's Equity Statements 5 false false R6.htm 00000006 - Statement - Statement of Cash Flows Sheet http://cannapharmarx.com/role/StatementOfCashFlows Statement of Cash Flows Statements 6 false false R7.htm 00000007 - Disclosure - 1. Nature of Operations and Significant Accounting Policies Sheet http://cannapharmarx.com/role/NatureOfOperationsAndSignificantAccountingPolicies 1. Nature of Operations and Significant Accounting Policies Notes 7 false false R8.htm 00000008 - Disclosure - 2. Going Concern and Liquidity Sheet http://cannapharmarx.com/role/GoingConcernAndLiquidity 2. Going Concern and Liquidity Notes 8 false false R9.htm 00000009 - Disclosure - 3. Assets Sheet http://cannapharmarx.com/role/Assets 3. Assets Notes 9 false false R10.htm 00000010 - Disclosure - 4. Accounts Payable and Accrued Expenses Sheet http://cannapharmarx.com/role/AccountsPayableAndAccruedExpenses 4. Accounts Payable and Accrued Expenses Notes 10 false false R11.htm 00000011 - Disclosure - 5. Commitments Sheet http://cannapharmarx.com/role/Commitments 5. Commitments Notes 11 false false R12.htm 00000012 - Disclosure - 6. Litigation and Accrued Settlement Liabilities Sheet http://cannapharmarx.com/role/LitigationAndAccruedSettlementLiabilities 6. Litigation and Accrued Settlement Liabilities Notes 12 false false R13.htm 00000013 - Disclosure - 7. Stockholders' Equity Sheet http://cannapharmarx.com/role/StockholdersEquity 7. Stockholders' Equity Notes 13 false false R14.htm 00000014 - Disclosure - 8. Income Taxes Sheet http://cannapharmarx.com/role/IncomeTaxes 8. Income Taxes Notes 14 false false R15.htm 00000015 - Disclosure - 9. Subsequent Events Sheet http://cannapharmarx.com/role/SubsequentEvents 9. Subsequent Events Notes 15 false false R16.htm 00000016 - Disclosure - 1. Nature of Operations and Significant Accounting Policies (Policies) Sheet http://cannapharmarx.com/role/NatureOfOperationsAndSignificantAccountingPoliciesPolicies 1. Nature of Operations and Significant Accounting Policies (Policies) Policies http://cannapharmarx.com/role/NatureOfOperationsAndSignificantAccountingPolicies 16 false false R17.htm 00000017 - Disclosure - 1. Nature of Operations and Significant Accounting Policies (Details Narrative) Sheet http://cannapharmarx.com/role/NatureOfOperationsAndSignificantAccountingPoliciesDetailsNarrative 1. Nature of Operations and Significant Accounting Policies (Details Narrative) Details http://cannapharmarx.com/role/NatureOfOperationsAndSignificantAccountingPoliciesPolicies 17 false false R18.htm 00000018 - Disclosure - 2. Going Concern and Liquidity (Details Narrative) Sheet http://cannapharmarx.com/role/GoingConcernAndLiquidityDetailsNarrative 2. Going Concern and Liquidity (Details Narrative) Details http://cannapharmarx.com/role/GoingConcernAndLiquidity 18 false false R19.htm 00000019 - Disclosure - 3. Assets (Details Narrative) Sheet http://cannapharmarx.com/role/AssetsDetailsNarrative 3. Assets (Details Narrative) Details http://cannapharmarx.com/role/Assets 19 false false R20.htm 00000020 - Disclosure - 4. Accounts Payable and Accrued Expenses (Details Narrative) Sheet http://cannapharmarx.com/role/AccountsPayableAndAccruedExpensesDetailsNarrative 4. Accounts Payable and Accrued Expenses (Details Narrative) Details http://cannapharmarx.com/role/AccountsPayableAndAccruedExpenses 20 false false R21.htm 00000021 - Disclosure - 5. Commitments (Details Narrative) Sheet http://cannapharmarx.com/role/CommitmentsDetailsNarrative 5. Commitments (Details Narrative) Details http://cannapharmarx.com/role/Commitments 21 false false R22.htm 00000022 - Disclosure - 7. Stockholders' Equity (Details Narrative) Sheet http://cannapharmarx.com/role/StockholdersEquityDetailsNarrative 7. Stockholders' Equity (Details Narrative) Details http://cannapharmarx.com/role/StockholdersEquity 22 false false R23.htm 00000023 - Disclosure - 8. Income Taxes (Details Narrative) Sheet http://cannapharmarx.com/role/IncomeTaxesDetailsNarrative 8. Income Taxes (Details Narrative) Details http://cannapharmarx.com/role/IncomeTaxes 23 false false All Reports Book All Reports cpmd-20161231.xml cpmd-20161231.xsd cpmd-20161231_cal.xml cpmd-20161231_def.xml cpmd-20161231_lab.xml cpmd-20161231_pre.xml http://fasb.org/us-gaap/2017-01-31 http://xbrl.sec.gov/dei/2014-01-31 true true ZIP 40 0001683168-18-002736-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001683168-18-002736-xbrl.zip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
W&$1[<"K7FXZ[ZTVHR(0( MHWGN^I_IJ@S4^,)_VNP/VRH/,P#:&*0>TDR:8+H!)[@V,3FP G+X3@Q?0YFN M1$,:)6&)N6;=E%[$.-*F!W$LPVL^P'W,:V0)="D #&GW0=U[^A86<ET%!2^JF&#-*['4'>)*""MS5#=#&!6AG3ET =WIW"H! MQLFM^/<8)6ER'&PH%9^F](#GMJZ9=?$.PPQO>5JPB;RDN66NC8*WTUE6P*L# M649I*'2R1MJYB2Y,?- MU=0#+3)T3;J0*V/JE1+5S-BY"&_+$'L:5ZU+..H/SM,7@+8D:;EL&FO6Q&#T MPO9!E"^.PH0:'JN)JK34!G?CE1MN523FVPSWTI@^21Y)]AJ!W\:" ##;PE + MAAM*&;S/?C'TOL#OJ@3;P&]_[)[)+3E^;I&G4*2$6<^:8KZ=,8MR-G/@QX/6 MAKU9EP)\LMG=L#J+[;6AK74X(^]<;UDDEN7!!*OHF=^Z)5:$@?"5I@$AH;A- M=H%C,ETY$]:E!*^,=3>M05E[=3 ]KCOFSBIQE*W3C#G"C*V2IR*RG/T56D8, M^^]KKU):-URLAU\29D:4Z[QA.]4A^E<;8U0]JTD/:I]J@5D1M\Z_EE<4Y.D3 MIB%:K#DOXWR+9O>8/N!@BUXQ?[%OK_?%SA14+_=EWNV;F+_I<;O.WZ+*Q7TC M\[>K*,%)\ KS-V-! )AM8:@%PPVE@/$F]H;>-W^K2@ X?ZN-1W-2!%AFTU5M M&7S+$^=;.&!F]:$\81NC=&ZP21<,:QT!=Z9KA3KBKQ"]9_IA^L0O^/B@" 5_ M<9>LV<+@^!A>OD8=\AV9RIGA>2"2!)>WBJ@6R^UUO6U:N)I3[5;8*@Y.OGW0 M*N_CH(6^W#ZK2I#)/.H7R@"Y/NY,]2+V* 3L!7)G'5(ZEP#EF.J+T .Z2DY# M79$AAU4TOUJDN(.DN)KD*3%<)6.EYHV>#D94A+30@=%!V@-5>I!B1+[E%\=4 ME\.DI3JL:V+J/LCN0*/,#JHZ*..@-Y3?:#1#YS JE0;GHBM2LXO(K\W*^/@< MU)*_PJ"A_03NQ3- J%/SETW)W\2BDQZWU:+3JIJ,0UMIXL:.DI#_P[N@*WT]50VB48Z6]P2=D[LH M27B/-5V)#V:]TXJW6\$ L]VZ 7>N7O9T^XKU.QKQ->PB2\1NJR<)%2/P993Q M&HV7T&X'+RD3S'SBE0SIK+0$]R3 M64EW$R6,_GJQ6:\E'AR7+7.2K%+Z(/#V)3:WU?::X]S-I$8*13O5P=FZ']Y. MEUG31KN.%@8Q)TE.V.O*^5([F\AH7D!'RN^!."7$YH&WA@@8XJAQ*9U0L3>Q M$GL64@<*/WA.WR5^)ED?1;J"GH]-:H"V3D:VI !Q10.MCRXRZ3+7@T&98O.$ M7U:6QE%@D<; MI$G&<(;BCW.<11D/,B<9'VO%1YLL2DB679(LH-%:#-;BO'SKM2S)Z[?" M#OQ,KTDT?;R^1CK.0SX03%/S865GX1GGS(_D,Z'BJ"9[KIB!+Z*[)%I% 4YR MI&C2P-LQ>Q?UMS5=%0L*.*ZN$^H;45ZI;!#M*#]RGV&#NQB86&&&M*'7 >DDU"O?X. M[,6E#;#2M:_)BF4PUZ+ L/IE^#4+:!F:U5(I%@6B,:A4BCRT.))7^?'XF52L M$9 D<(H7<2O#:W#(/N8U(D%<"@!#YWU0=S88=F7(V*AZ*;4=3' ]>0VX?8?= MIS00:2V[7[,&1%K:=Z8U)1C\$AD>O^(\)[33NOIH9JGKDVU.YM1)9Z4(AGLN M:#L7C.Q"BNHC>>W:(W"7*/ @UGS;,W"WA7S23@VPSJ^F!!@B*6&U&2.%P V- M(MCN/HU#U@@DQ)LT)_:CI(.^UT5@5[,::\"VRE 6=/8%KKR2LM#_ Y(EP*!I M%01C/04Q:@P2@&0WO3"(@^GP^C$JTEKS:"2F GF>H+"KK_\SJPS,,V,O9Y*' MS+2^3FQ'-2B>%]^@(__8,*]P_&@1I* 7][V-:@+=WC15R8*A40_ ;F1V*8ZD M/+B>JFV0S6:]1GY(4O5NQ2N%P=*JU[]J\PH&F8I0M%:@V5;^[&.6K;)/FKD9 M5.><:_-^ MM(5\,DP-L,ZDI@08QBAAM9GQ;3'FO!@OEI.OH^5X 8,4FI0,5KV4I2Z W!K] M?925(AC"N:#M+/2/%C^AT=LG&9?3&Z^R"]@ M<&_RL,81Y>UH2LN[.J:KZS2YNXX>22A#">T8N5]17M?=7F!L8SUNCW+ WGPYOI[\S)C/.3]ATY2;+Y/SZS$:+19C*(2_8L:+ M]!-?">9KE+LAQ([E#OH^J>UL5IW/ULI@2.R*N,W<*\9;Q#S4;V,QK98$%;2] MGHS.)]>3Y03*7*HRM78>:I)D.=T\[-SSOM=DUAV$J#;F*$EJ4H1'4 NT'7). M;D8W%Y/1->M#%\OYMZ]PYE'5)H^E2Z 5'V2[S69HU\B"(58/P,X0?7,Q_3I& MR]&_0^G/+M*'-27W),F8NR&M<1E_[=4]1WTZ&=6*_[32!4-!1\"=I:+IU]E\ M_-/X9L%\1500]/WU=+'X (.A8TQY-E">0E;<2F!'S%XMKP%Z=B8T(O;,*F#8 M9X=3TP]*FJ$9FXTO?AK-QS (QQL4:TTB2+6X5N@BS:P7S&VU?7>(#B:U^T,+ M53"$=,/;V6A>3B_^=GP^6H@%HZ\SUBT"VMU;D#ONK\[).J6NV\V6NEZ#&ES, M:00XV"B"8:0+VLY6\[?%Y&:\6*#%^ N@B<<->:IMG=,T8;\&I#:7LN.D>S%^ MKZ'8S\CF911N98 A[9[ V_R=CR\8:Z]_19/%XAM?BKRXF'Z[6?)E]]E\>L-^ MOQCW\OJ@>R6[:Z_5.R.[[SUGX[<(6U>B4]RI7 DA(D_,PNA%)DG.@$;\D+!8 MYK[84-K-+=TK[3EUJ@ER*X6J2A1,"S?CZP8'E]+%Q?$P*"2@[_90BIU!C<4Z M8:^) HR &WD E))@Z&.$I\R!@J)*&@52' B)V" 71O$FCQ[)@@0;*@X?CI^# M>!.2D-\?QB<5FS(/6GO*.WI07#[XRF5[I>AKOHX&HU^C8#@-X!6MZ;276MDH M$W=Q_N>\_^8':"Z5&VQ5)NF!*JIV;%I5';6O/?NQIC:D0M4],6YU'OR0ZQ2= MTZ'*18F.E&=V&]<@].#,9UDOR2H*HA?GSM6XC5TIX2UM MG1I:E:NN^?7@]:S'U*[>0@@54@,UJ=[94W-. J?'4N-JO^0EOR41!5(*UH2I MDYUKFM\3VDW1I;/?7G_8_&L]9IDSKFF4X;#0$;&:G[C,K;:NY5;#14868I%; M[:#N3)DG9DXR0A^)H:_0R<);L.M%JDA_)VHCYBEW:I=P >E-BC3YR=TUOZ$U MN]KP_/E?HR1ZV#PP;LKT5+OY0>MM6&M[31OO9E(C,;R=*IA>Q UOQR\7U_,& M54HQ&(P4J,;/ZTA>WW")39) M),-U[<';X[T&U7A^J8V>T=.SP8Q]G@WNK.5@*L2*7AE&J[Z(<99-5P6V*9U' M=_?Y^)G0(,K(C$:\^RJ!%]]F.A=MS[*\AE:^Q-S&ALD^!8%I"2]!KZ$U$OJ@ M6Z,#AO$_Q^CW@NKQ,T3N 1!,[P'QK>AZI:>B&(1E.2B.5B_NG'3[8_*9U?%% MY:Y/1\;?'ID&WFZ7K"4P..%,J'05OF)RZ)$+OO$AJ-LD;C8/MX2^=J/4/^=- M# 5]K^E5NG/=0P9O(8>VK'-'J!1'Z4X>1C,;/ZSC=$O(@M!'YGZJW\=-FCR2 MC \JW/1,[*O5O^='CV[2_%>2STF0WB71/TDH5FT*LS4OW].SO9Z!]/DZ&R*5].Z8 M=16&V:34 5?O2[:EP="V%V+GJG9&I[140C'30D%=#3K!FAMFSF^EK0Z#?&JC M[*C8U'T#Q%0"[GHW6HJB6W(GYI\#;XC*2VV+R"$>9K*[BZD(+YIT-]2LE7X+ MT\!;1;)GB56 QG&^^LS/ ;%M)$X5/!4E_7MKAZH^N8,VN>5G,A\'T MB%5X%+(?%.6L0+06)0Y1Z>)E>L$Z'%+$ M"7:JVUX55D4[X^Z4E\ WP].R#.:UBD)XK?/K4D@9'#E$Q;KUPF^H M^]VGW[V&V-^V##G?5K$UG$1]5=02!UU':JR]E72[E94C.E.N.$0M39* \HBS M2R+_G21%N*V:AYUJ<]2'58_[@5?<"26T3]Z7Y7S@#:\\V:!SAH:H[4MRF\]) MS#&&DV04_&,399$\>WF!DP1?I'%*<9AVJME6$5;].J+N9H6XY>LQ4I]7*=Z5 MP$=&408J"WD+/NU9IV*=2X!5P_O"?^-N+3]#RX,=N:M6^'2%J_>4Z/Q9"QU8 M=6L/6'7$6$9TWG)?MO)7TU)]2,^UR+%;BS2>)+LS+[M!IU.!MHJP:M$1=;LJ MA7H5DULV4-8LX]TEV;NQ=9!E(7%RL>=>3+,DK!KK@]D9)G=WKJY83RE/AU&\ 9,H4U>@T[_YXG[U]USK,&H)JP!-II"UP-U?6J1E&H#M4NG*KI M+=20>^5 K)9=_RKS*?)LU!N&K^A4TR0[)VQ>3JIK>'@"QISBE(91@NEVDI.' MC!D6\",>:1R+ER$[!W77=[#' :*&#RL5^TB[L4\N7^X>C'9/1K?BT27_Q,./ M4/-AJ'S:4)DCQ'IZ+;Y=1:6.T&_?@R& 'IMZZ^ (3>V"\P_YTOD<8T[6[#W< M\RVK;@8+92WT:@%JEPY@U9'7-5TDE9'4/D*+(5-UF S3YH_M57HC-=?$ZEQQ M/P^Y*!?^QR83N9VR93H*0[$YC&.^\3A)BA5<0:S;]@&#.9&;R>4Q!&E-<9B M"VBK_=#/!,0:;Z9VEBAW#^;[A[M'(_YLO@%5/+WH-X[ED8XZ@B-484 %B(*R MJ 9C(-Y^P5'"'8WB^J=EVK<%Z:0(B$%N>-LTX-JE1U:4P.FP*P,M!MU\?,TP MR.&=+P>0RN@ZG=9P,[-6>)F8W+/&3Z)'#D_IC_5K 6I=#F!U87.H&38GUS]J M!8"IO!DE//['N"QHU@%=<1JHEM56: ^\G'A#O+ MHR"/'K4YCNVU 57D'J!5YP1%R%19" ]-?O]-!CU^0+O5^5U90R4T+#*N,E^0 MAV)2PA S=/EVQ@S*1XG(=;+6N2[VVH#J=P_0G22'11'"D96%H+*4(R3*.:IV M&M<#N#)M6Z]26D_I*(:$2[).F2NM;+@V>@"KU JNMC)YK-7[1O[*#\7@698! MJQ.>B//T^W;""FU -;H':,=.N"IJN$YXL(AS(!.3_8&KEXP=2H+5DJ^B!"?! MOBU9H0V_)9M .[;DJJCAW2GU15Z2<^T)@JJ&7?0!U?%>L)5G#+C3)'ZIE7-4 M+O(I9DIO-3X=2 _<#U =::K0 '--VDV:DY[*<58&U-;<,9OO6I-E(%X(JAT\ MZ#EM4/_HFOW&/BX_8C_XTCW[Y/\#4$L#!!0 ( '<]+DTY*!&+-AL !BE M 0 5 8W!M9"TR,#$V,3(S,5]P&UL[5W=<]LXDG^_JOT?>-FZVMD' M?R8SDV1G;DO^2OG6L5VV9[)[+RF8A&3>4( &)/TQ?_T!)"51$@$T*%)H>9.' MQ)'1$+I_C48#Z&[\]/?G<1(\4I'&G/W\YF!W_TU 6)#2C\A?E%W\,WNT>OKT/=G8 _?Y* M6<3%+S?GLWX?LFSR<6_OZ>EIE_%'\L3%;^ENR&'=W?)WX0,=DYV8*9A"^F9*I7IIHCOX\.'#7O';:=.5EL_W(IE^ MQ]N]Z7!F/T&-X%#TE6:)GU:P)M"_6_G6FS'?71SL'ASMN# MW>C,5?B%!P1-Z0X>!^E4RWV)$KYF+)LP*)3EL79BX), MME$CEEP473X(.OSY33@91SM*)0X.R^_],X0V>YG(J9/&2O/?!'OK#/6()$JV MMP^49JEM;(V-^QK,-1%2# \TBT.2.(VLD;+#8:I)1Q5&5\.KB3)+$AJK[(Q$ M_0SN-N/A;P\\B:1A//T]E[KD,$@]<3^#/2;IPUG"GUP$N4+3X= NI6$5M Z6 MG)&W\8C%0ZE6*R_V,NYXI@\NLO8@EM M!- ,&UV'0QRD*< 6+;;J\NM+&*05>2'W"97,RD]$3J/3YPEEJ1UG< <=#EIZ M0>,X4[/".KR&IAT.Y"+.XE&AW7.^;VF6)<64O8C)?9S()G8I.G?4J5ER-YP; ML);GTI<>TSOR;)=>0],NY9/?I_3W7.)P^@A1.5U[K^:Z/[/=H_EV'\P)S4B< MI)=$*()'VCV[NF_8P*KERIQK/YVO:JX#-E-MA3UM=4Q%QR$*F3>+/0EYH"I?\6 MH_0;N?8!PT".)E(C.DO(J%G\2TV 8G^'2>R-7/H0]W$N%(MG<1J2Y%^4"*/B MZUL#0?@>$P@VWOTMO%]HDOR#\2=V2TG*&8W.TS2GPK0 :TF R/R "1F0%/S! M\RM/Y":6B)?BLCDUP;+2% C'C_C@T'#MT3TMY^\-G7"ACI[*:V^CEZJA (+R M'A\H9AGXPZ;0D6-I3$=<&#<.2PV!2'S AT0CQ_X N,[ODS@\2SAIVO7/1KW0 M#+QGPR?]!G8]&B8^'G-6'+[=/DB^TZL\*\*;Y 0UFB*#?C&M8;T/AI;X6["_E! MOZ?BS0%?"\?@A\%., O)D3]7)$%%LZXN#4EZ7^"2ISLC0B9*H7[3NM=1+L MXH31L-*]Y5H7CLI'AZ*RTMS;N6)7X&@$@ ,C%2XH[;3Z1UV1/I)$#C4=9,=$ MB!?IGQ1!U'K,@.3>#BE!0/ V+&$"\5K0"8FG4005FWK0-,V]'6*V ,G(,0Y0 M%M@!6CV/YY4=6[L&+"0K0RI_&5V40M .N!AMQC.2%"T1H&B#S^?VM"O@7@MB MM3!8%:6W$@-D=T3@/4!1[VUA6P-U5SGAL*JU48,=2Q,-%$&,!M M5QDP&%J73J"H=G_/!(>&MV^,.%XR3.J&6Y"TC0>QC2RPNG4"135WG8:SJBVD!$.<%W\ MDS7[^,/>W,XUX-V6??OU5-&* M 5MN%1H;0U'JS24%B'KED%K',PY0:H$IMGN>E9;@:SDT<.BXQ8'%((J*^2YG M/HFCT&$;]!VC]'^ MG@>.>&]WXCW>[_2"O_^(O.9"9POA>6^-X7G!=PM=_/5;N-YF]@12ZE>B&'-4 MN&?75!31TM!M@I[>5T;\^G/834(X5MG%,9^ B_F,^KVUHKM)M<9 F M3"1XX2LR#QVAF])X2\KO![9%4>"%S)QS8V"P3=(-1H<7*!0<"-:.)MR701#Q M%L<5.@@''9KPY<](Y"UMNE/T<"]\*P.UK7I: F_YU#V@A7&]#W6?J0L M-UV%SUOXWH)9!+YR/+W(&0[C56DN&TUK?MK5QD#BVT%W0\3*.PZ(RH=5$A6# M&XUC5A0E5$4XJU'K@;(2^LZ#LP/ W1C"!%NQ^!V1E$;J_1LYOH5"I0WGHYKV MOO/@7$$R\XT#FQ6>'*R=_\VK*R):;K?]KFW&6&GW+W@* ;+>V/=.MC64JQQO M/9C9 Q4E6ZI2!]P=L=#YWOXZ0PR2 PX[>LXR*L6965V1E8:^-[A *7,S%VUG MWH=RYC$Z4F>'_N?>)Q(S94NNV$F<3JI]_M6PS,0],'B8%CI_-T\57VLJ-O"- YAB2)><\<45VVHI;73^:INM Q=,&JU=F$ZMSW/I,".^;JJ:5<,CL_!3ZB0RYH[0&5 MTV/P.E15 MLEZ)](@R.C2%AFL)O-IF/[ZFX M&E9C=;C1=^X("FY_]R]MP&TI+X17_H8DA(6K_^]-5_^U3OZ2!E4W*&+TV^4E M@\B]9DU5([Q3]1L G%3M;)-M14M[F7%.\*SD3"UR5#\\PP"(G)ZT<*D!H-3: M(@-F0:UT"-2&7Z]:@P&%4I74U2MG5%6*?8XA@#23;2,VS9S48H%\.HJ+8SOA M8Q(;0@(TS9&A8M*X9<>PF:%:G F..,[/5#DU>F :FOH.1FL#AY9C')ZY)@_? M!HZ%#$T&D -0($G@ &TY"]^&EJZ][U#"-C"9><>!C\.&=HUGCWI'9<79;(I" ML^Q#W]E&-U3<3=0YR6XVO 2/7CWHWO &X[4.WX0C?Q;N@D%^&# M"CU?-1J6*6>A]1WR[3;90(+8_JA%$Z^6 H( 4M^AX9U KJLLN*6(#Z+_R]-, M"26]XYI-L24&TJ$+WY'C8 UP%DM/2^P185(1ASF+KH97CU1$@@RSJIS5'3]. M>$JKDNJ:Q=6E ]\1Y+!EU5TDB!94G0-NF6(06N^1X=UL11 &'IO<[7; U4F] M1XMWLNU "!O$AG\A0A"6V2J!M.C*>U1YIVM=HYQPP&RT)N7G9US<4O$8A]9- MBT,_WD/)N[&W6@FA1K>P.>N#J^L&S[-_Z]CD[82V5,M+^E3\JNV$K=%[#\7O M9J*N2 0UBH4"M@=QF1S/*X[K3$BD$$(<@$('[Y=K4-S0\K"95A:FY/6&AGS$ MBEXLAT;]?[/W)(M.W; N4'@%*8&]9G?X/WRR971L::S#UT,$*3;MPQW4\#NY M)S]E",Y]UPMW<("RO\_EB+#L4CVZI_T=EZXAM3[3$A%XW4N^.?*N69AG- %9N]X9U.]GV]#$^$$ M-P9]BAV'N3BA$H8PMA2S7&SE.P*J5U2X@7%,P&VX'FEO9UL;!!-\EZX+*#BWHA,01H-Z_C=)[C-2FU*-99*]1.:I$EK3R M@]0S36$HHK(ZQ;24$3-, M0E(46\/Q.7ND:4>A1,:^O)?.[DY+ #+#80FD>9J&A*O"+H)*3J2&9R_7"6&9 MJC$M/YV8SYA=^H!BW-N9TQJ \=9BI<[, D=;V&P2XV+IP%>!Z MTG^>7A\NPBMW),]B1EC8C2-I[ NJ)?VG8JVM)0"9(5DE:L;NADXJ*W@UK)UO MO)S0>Z!?8.X!BF]OYPEK@*5W"B!2Z^E<2'V%_$IUCA&I$ZI9B4>EOXR18YYP M02*N.1""DX/+F>)%SHWA7F%SK0#9]"YPFTJ2\'>"W_86,-0-D*TEZ#.46*,- MQ4HCQ:0*F%6%RJKZ94_,7,0-1 E%?-,)1(Z(.T@)W\(Z#TNM/00!6U$UI%!4 M-WT>L]Y2:I03#ECA?'?A&\.!QA2]XRZC;=\Y*78'K#!2ZC3HD23*'RS7GN4; M)[U>N/4"U0Q,>^HV,=IIM;,'.=* 2*-OYE2=QAK1;<.0/F!2EZ.#D4N][N93H#@K=A'].&X3:?3,IQD60J ME7,VY&)K/ M2W.4]W)49"/C6%!1R4=WY)FF &!6VT*QZ:\&W9K8Z-AO@,=+-;)+DDD+?S6L M0O$X4Y&;M_&(Q<,X5*$4Y3&>JHW*DSBL'P\LU"K[,=@)YBN&_,_!;E#VK8J5 MS7L/"(N"6O_!_ N"V3=XK FQPBZ@_(^!QF?NNA@1%O]1B/U82EZ.+2K^"<*I M))FL W@UK/QHDLS<+H !Z:A[K_[TO2J]FLF1G?#\/AO<\SRK:P/ <+CTX=D* M=*H/*\ZWJRBQS/XR\:-YKG]8GNMO=X.J?8=;^;)'T(F,:J]OWN7YPO*WF*9" MTZ@0J+U96*N' E:6.[[Q]Z/NNH3$*M>U>28<["_/A'>[4Q\X#:J^BH6OZBV8 M=>X>>5S$ JLOEW=83'9:%2L4Q MQ&6IE.8Y>K \1[_?#>I$'N\FYJ-0MS*\V!=0%KI>1+AUX_,R9CY2ITEIH_,\ M]UKAN'RO A(-EDDWOQ28FXWY]4!3$O_"E#Q/NJW@-\O M3Y\/^FET;V4?P.F)Y3>]UMGSC?Y;H+!$7[U M2RJG[6F:Q6.2F9*?EMOY?M_,&9QF1G& H,FO@4XH(#DX&QP+9$YBP8&DML@0 M&$QX#[Z??W/&TU4X." ]J?;_Q]+K&5'XK+31>7_TS14^F"!P@'8^GI!8%$'M M0CJ2$YZ2Y&IXP=GH(GZD5?@!&,IVO7E_",X5X'6$A@/V,SG^(M_D,R5JYS W M+F"L';H MQ;XH8SP,[B089J+5KNG$E.\_'<(0 @:B;W_@A?:S0A8L&!Y.P4 M$&YZM13>W\=S-J\6YG% I%[R%/2!LE3:_'+(CA84WH/_=]"@M':G%^89.N&AQ= HD]_YVF#.83G+! >4E?:JQ*3B3/X:TYGJ!477OR?O; M8U!I-)G)&D 0C5:KF1[P#I7A!H8A27 MMU35]@+Y1OJJ;YVY02@KP;U"U\-K3;DU/0FO&2-4[H^G)>&L1S6:YM[7'%XK'VU3*!UB 1 M2!>^G? N*BA:Y(/#8LXKK=U("8M'^TJFI_!]D><.FHW[UU!/J%Y,$&1^+34R MD1G9?[L2?%5L(1M=J&<;T[-(RAO2$9+3I3?*I#6ML[?OJIIH0B,FN[ ME645MSD&&%@G\5O<[[>X7T,AMCB*B7BY)U] MNVIP-5PY$#8) (%'=FP]?<&LD\@MB\9@9J!]@>H;BADUR$ M#]*G'XP$+5A9'J[-ZCET@0,TD_HM0>? VYKF3W.S.K_,IN(Q#FFJ-6BJN;:U M[Z 79S6KW]!;9(##I@V>B(CNY+=87FOF^$>M3_9>P;Q00#M.[D4RW_A) -H/X:T&4.'"PK8AH#S@,NJ0'HF]77J29;9TI_=W5AKY7&NOQ@V[@W1@8C4AO M:ZH,,8\X1KF MUM0J02:W7H\=JIDV>S-"<^:PV@P<5>(/SN:!OPI#LJI/E[GENJ#[K_)>Y+__ M&6V3,V8U\8PD]=^K MIPLN>?8OFMW0D(]8_ >-:G=?AM5_0U_O_4T!L,YL% \L^2.SQX6@R=%OEQ-' MWN\&92=!T0NRA!' B_.&QZ.0I=YM=RH) (IO>27(KNX1YY7,U&F09P]KH;"$5>@H\[ M1IN6U#?G&A9QN._SU&Z>ID6AJ"$7A5.H5W@3S=9<^-D9QP[08DYW&[B6>]B: M*SU7H3CM4ZK?J+_NY<9)?O+_4$L! A0#% @ =STN3;D%'4DI10 OEH" M !$ ( ! &-P;60M,C Q-C$R,S$N>&UL4$L! A0#% M @ =STN35'IT_KP!P RC\ !$ ( !6$4 &-P;60M,C Q M-C$R,S$N>'-D4$L! A0#% @ =STN30JU5PPB"P @8, !4 M ( !=TT &-P;60M,C Q-C$R,S%?8V%L+GAM;%!+ 0(4 Q0 ( '<] M+DVL'BN3_ P $>J 5 " &UL4$L! A0#% @ =STN M33DH$8LV&P &*4! !4 ( !6(\ &-P;60M,C Q-C$R,S%? =<')E+GAM;%!+!08 !@ & (H! #!J@ ! end